<html xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:ali="http://www.niso.org/schemas/ali/1.0/">
   <head>
      <meta http-equiv="Content-Type" content="text/html; charset=utf-8">
      <link rel="stylesheet" type="text/css" href="../../../../src_test/resources/css/JATS_NLM_preview.css">
      <link href="http://fonts.googleapis.com/css?family=Roboto" rel="stylesheet" type="text/css">
      <link href="http://fonts.googleapis.com/css?family=Tajawal" rel="stylesheet" type="text/css">
      <link href="http://fonts.googleapis.com/css?family=Montserrat" rel="stylesheet" type="text/css">
      <link href="http://fonts.googleapis.com/css?family=Lato" rel="stylesheet" type="text/css">
      <link href="http://fonts.googleapis.com/css?family=Source+Sans+Pro" rel="stylesheet" type="text/css">
      <link href="http://fonts.googleapis.com/css?family=Quicksand" rel="stylesheet" type="text/css">
   </head>
   <body>
      <div class="meta">
         <div class="article-info">
            <p class="article-info-title">Article info</p>
            <p><span>Subject:&nbsp;</span><span>Research</span></p>
            <p><span>Subject:&nbsp;</span><span>77</span></p>
            <p><span>Electronic pub date:&nbsp;</span><span>2018</span></p>
            <p><span>Accepted date:&nbsp;</span><span>13/02/2018</span></p>
            <p><span>Volume:&nbsp;</span><span>360</span></p>
            <p><span>E-location ID:&nbsp;</span><span>k872</span></p>
            <p><span>Publisher ID:&nbsp;</span><span>abrd041828</span></p>
            <p><span>DOI:&nbsp;</span><span>10.1136/bmj.k872</span></p>
         </div>
         <div class="journal-info">
            <p class="journal-info-title">Journal info</p>
            <p><span>Journal ID [nlm-ta]:&nbsp;</span><span>BMJ</span></p>
            <p><span>Journal ID [publisher-id]:&nbsp;</span><span>BMJ-UK</span></p>
            <p><span>Journal ID [hwp]:&nbsp;</span><span>bmj</span></p>
            <p><span>ISSN:&nbsp;</span><span></span></p>
            <p><span>ISSN:&nbsp;</span><span>1756-1833</span></p>
            <p><span>Publisher:&nbsp;</span><span>BMJ Publishing Group Ltd.</span></p>
         </div>
      </div>
      <p class="toc-title">Table of contents</p>
      <div class="toc">
         <ul>
            <li><a href="#Abstract">Abstract</a></li>
         </ul>
         <ul>
            <li><a href="#Objective">Objective</a></li>
         </ul>
         <ul>
            <li><a href="#Design">Design</a></li>
         </ul>
         <ul>
            <li><a href="#Setting">Setting</a></li>
         </ul>
         <ul>
            <li><a href="#Participants">Participants</a></li>
         </ul>
         <ul>
            <li><a href="#Main outcome measures">Main outcome measures</a></li>
         </ul>
         <ul>
            <li><a href="#Results">Results</a></li>
         </ul>
         <ul>
            <li><a href="#Conclusions">Conclusions</a></li>
         </ul>
         <ul>
            <li><a href="#Introduction">Introduction</a></li>
         </ul>
         <ul>
            <li><a href="#Methods">Methods</a><ul>
                  <li><a href="#Data source">Data source</a></li>
               </ul>
               <ul>
                  <li><a href="#Study population">Study population</a></li>
               </ul>
               <ul>
                  <li><a href="#Exposure assessment">Exposure assessment</a></li>
               </ul>
               <ul>
                  <li><a href="#Potential confounders">Potential confounders</a></li>
               </ul>
               <ul>
                  <li><a href="#Statistical analysis">Statistical analysis</a></li>
               </ul>
               <ul>
                  <li><a href="#Patient involvement">Patient involvement</a></li>
               </ul>
            </li>
         </ul>
         <ul>
            <li><a href="#Results">Results</a><ul>
                  <li><a href="#Sensitivity and ancillary analyses">Sensitivity and ancillary analyses</a></li>
               </ul>
            </li>
         </ul>
         <ul>
            <li><a href="#Discussion">Discussion</a><ul>
                  <li><a href="#Comparison with previous studies">Comparison with previous studies</a></li>
               </ul>
               <ul>
                  <li><a href="#Strengths and limitations of study">Strengths and limitations of study</a></li>
               </ul>
               <ul>
                  <li><a href="#Conclusions">Conclusions</a></li>
               </ul>
            </li>
         </ul>
      </div>
      <p class="toc-table-title">Tables</p>
      <div class="tocTables">
         <ul>
            <li><a href="#tbl1">Table&nbsp;1&nbsp;&nbsp;&nbsp;</a><a href="#openModal1">[Click for popup]</a></li>
         </ul>
         <ul>
            <li><a href="#tbl2">Table&nbsp;2&nbsp;&nbsp;&nbsp;</a><a href="#openModal2">[Click for popup]</a></li>
         </ul>
         <ul>
            <li><a href="#tbl3">Table&nbsp;3&nbsp;&nbsp;&nbsp;</a><a href="#openModal3">[Click for popup]</a></li>
         </ul>
      </div>
      <div class="article">
         <div class="article-title">Dipeptidyl peptidase-4 inhibitors and incidence of inflammatory bowel disease among
            patients with type 2 diabetes: population based cohort study
         </div>
         <p class="copyright"><span>© Author(s) (or their employer(s)) 2019. Re-use permitted under CC
               BY-NC. No commercial re-use. See rights and permissions. Published by
               BMJ.</span></p>
         <p class="license-oa"><span>This is an Open Access article distributed in accordance with the Creative Commons
               Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute,
               remix, adapt, build upon this work non-commercially, and license their derivative
               works on different terms, provided the original work is properly cited and the use
               is non-commercial. See: <a href="http://creativecommons.org/licenses/by-nc/4.0/">http://creativecommons.org/licenses/by-nc/4.0/</a>.</span></p>
         <div class="article-meta">
            <div class="contrib-group">
               <div class="contrib author"><span class="name"><span class="surname">Abrahami</span><span class="given-names">Devin</span></span><span class="role">graduate student</span><a class="xref" ref-type="aff" href="#aff1">1 </a><a class="xref" ref-type="aff" href="#aff2">2</a></div>
               <div class="contrib author"><span class="name"><span class="surname">Douros</span><span class="given-names">Antonios</span></span><span class="role">post-doctoral fellow</span><a class="xref" ref-type="aff" href="#aff1">1 </a><a class="xref" ref-type="aff" href="#aff2">2 </a><a class="xref" ref-type="aff" href="#aff3">3</a></div>
               <div class="contrib author"><span class="name"><span class="surname">Yin</span><span class="given-names">Hui</span></span><span class="role">statistician</span><a class="xref" ref-type="aff" href="#aff1">1</a></div>
               <div class="contrib author"><span class="name"><span class="surname">Yu</span><span class="given-names">Oriana Hoi Yun</span></span><span class="role">endocrinologist</span><a class="xref" ref-type="aff" href="#aff1">1 </a><a class="xref" ref-type="aff" href="#aff4">4</a></div>
               <div class="contrib author"><span class="name"><span class="surname">Renoux</span><span class="given-names">Christel</span></span><span class="role">assistant professor of neurology and neurosurgery</span><a class="xref" ref-type="aff" href="#aff1">1 </a><a class="xref" ref-type="aff" href="#aff2">2 </a><a class="xref" ref-type="aff" href="#aff5">5</a></div>
               <div class="contrib author"><span class="name"><span class="surname">Bitton</span><span class="given-names">Alain</span></span><span class="role">gastroenterologist</span><a class="xref" ref-type="aff" href="#aff6">6 </a><a class="xref" ref-type="aff" href="#aff7">7</a></div>
               <div class="contrib author yes"><span class="name"><span class="surname">Azoulay</span><span class="given-names">Laurent</span></span><span class="role">associate professor of epidemiology and oncology</span><a class="xref" ref-type="aff" href="#aff1">1 </a><a class="xref" ref-type="aff" href="#aff2">2 </a><a class="xref" ref-type="aff" href="#aff8">8</a></div>
               <div id="aff1" class="aff aff1">[1] Centre for Clinical Epidemiology, Lady Davis Institute, Jewish General Hospital, Montreal,
                  QC, Canada H3T 1E2
               </div>
               <div id="aff2" class="aff aff2">[2] Department of Epidemiology, Biostatistics, and Occupational Health, McGill University,
                  Montreal, QC, Canada
               </div>
               <div id="aff3" class="aff aff3">[3] Institute of Clinical Pharmacology and Toxicology, Charité – Universitätsmedizin Berlin,
                  Berlin, Germany
               </div>
               <div id="aff4" class="aff aff4">[4] Division of Endocrinology, Jewish General Hospital, Montreal, QC, Canada</div>
               <div id="aff5" class="aff aff5">[5] Department of Neurology and Neurosurgery, McGill University, Montreal, QC, Canada</div>
               <div id="aff6" class="aff aff6">[6] Division of Gastroenterology, Department of Medicine, McGill University, Montreal,
                  QC, Canada
               </div>
               <div id="aff7" class="aff aff7">[7] McGill University Health Centre, Montreal, QC, Canada</div>
               <div id="aff8" class="aff aff8">[8] Gerald Bronfman Department of Oncology, McGill University, Montreal, QC, Canada</div>
            </div>
            <div class="author-notes">
               <div id="cor1" class="corresp cor1">Correspondence to: L Azoulay <span class="underline"><a href="laurent.azoulay@mcgill.ca">laurent.azoulay@mcgill.ca</a></span></div>
            </div>
            <div class="abstract">
               <div class="title" id="Abstract">Abstract</div>
               <div class="sec">
                  <div class="title" id="Objective">Objective</div>
                  <p class="p">To assess whether the use of dipeptidyl peptidase-4 inhibitors is associated with
                     the incidence of inflammatory bowel disease in patients with type 2 diabetes.
                  </p>
               </div>
               <div class="sec">
                  <div class="title" id="Design">Design</div>
                  <p class="p">Population based cohort study.</p>
               </div>
               <div class="sec">
                  <div class="title" id="Setting">Setting</div>
                  <p class="p">More than 700 general practices contributing data to the United Kingdom Clinical Practice
                     Research Datalink.
                  </p>
               </div>
               <div class="sec">
                  <div class="title" id="Participants">Participants</div>
                  <p class="p">A cohort of 141 170 patients, at least 18 years of age, starting antidiabetic drugs
                     between 1 January 2007 and 31 December 2016, with follow-up until 30 June 2017.
                  </p>
               </div>
               <div class="sec">
                  <div class="title" id="Main outcome measures">Main outcome measures</div>
                  <p class="p">Adjusted hazard ratios for incident inflammatory bowel disease associated with use
                     of dipeptidyl peptidase-4 inhibitors overall, by cumulative duration of use, and by
                     time since initiation, estimated using time dependent Cox proportional hazards models.
                     Use of dipeptidyl peptidase-4 inhibitors was modelled as a time varying variable and
                     compared with use of other antidiabetic drugs, with exposures lagged by six months
                     to account for latency and diagnostic delays.
                  </p>
               </div>
               <div class="sec">
                  <div class="title" id="Results">Results</div>
                  <p class="p">During 552 413 person years of follow-up, 208 incident inflammatory bowel disease
                     events occurred (crude incidence rate of 37.7 (95% confidence interval 32.7 to 43.1)
                     per 100 000 person years). Overall, use of dipeptidyl peptidase-4 inhibitors was associated
                     with an increased risk of inflammatory bowel disease (53.4 <i class="italic">v</i> 34.5 per 100 000 person years; hazard ratio 1.75, 95% confidence interval 1.22 to
                     2.49). Hazard ratios gradually increased with longer durations of use, reaching a
                     peak after three to four years of use (hazard ratio 2.90, 1.31 to 6.41) and decreasing
                     after more than four years of use (1.45, 0.44 to 4.76). A similar pattern was observed
                     with time since starting dipeptidyl peptidase-4 inhibitors. These findings remained
                     consistent in several sensitivity analyses.
                  </p>
               </div>
               <div class="sec">
                  <div class="title" id="Conclusions">Conclusions</div>
                  <p class="p">In this first population based study, the use of dipeptidyl peptidase-4 inhibitors
                     was associated with an increased risk of inflammatory bowel disease. Although these
                     findings need to be replicated, physicians should be aware of this possible association.
                  </p>
               </div>
            </div>
         </div>
         <div class="body">
            <div class="sec intro">
               <div class="title" id="Introduction">Introduction</div>
               <p class="p">The use of dipeptidyl peptidase-4 inhibitors in the treatment of type 2 diabetes has
                  increased considerably since their introduction a decade ago.<a class="xref" ref-type="bibr" href="#ref1">1</a> These second to third line treatments have been shown to have favourable effects
                  compared with other antidiabetic drugs, such as lowering the risk of hypoglycaemia
                  and having neutral effects on body weight and cardiovascular outcomes.<a class="xref" ref-type="bibr" href="#ref2">2</a><a class="xref" ref-type="bibr" href="#ref3">3</a><a class="xref" ref-type="bibr" href="#ref4">4</a> These effects are mediated by inhibition of the dipeptidyl peptidase-4 enzyme leading
                  to a rise in glucagon-like peptide 1 concentrations,<a class="xref" ref-type="bibr" href="#ref2">2</a> but inhibition may also have unintended effects. The dipeptidyl peptidase-4 enzyme
                  is found in the serum and has been associated with several different cellular functions.<a class="xref" ref-type="bibr" href="#ref5">5</a> It is also expressed on the surface of a variety of cell types, including those involved
                  in immune response.<a class="xref" ref-type="bibr" href="#ref6">6</a><a class="xref" ref-type="bibr" href="#ref7">7</a></p>
               <p class="p">The effect of the dipeptidyl peptidase-4 enzyme in autoimmune conditions such as inflammatory
                  bowel disease is not well understood. On the one hand, studies in mouse models of
                  inflammatory bowel disease suggest that treatment with dipeptidyl peptidase-4 inhibitors
                  results in decreased disease activity.<a class="xref" ref-type="bibr" href="#ref7">7</a><a class="xref" ref-type="bibr" href="#ref8">8</a><a class="xref" ref-type="bibr" href="#ref9">9</a><a class="xref" ref-type="bibr" href="#ref10">10</a> On the other hand, clinical data indicate that patients with inflammatory bowel disease
                  have lower serum dipeptidyl peptidase-4 enzyme concentrations than healthy controls.<a class="xref" ref-type="bibr" href="#ref6">6</a><a class="xref" ref-type="bibr" href="#ref11">11</a><a class="xref" ref-type="bibr" href="#ref12">12</a> Moreover, such lower concentrations are inversely associated with increased disease
                  activity, although whether this is the cause or consequence of active disease is unclear.<a class="xref" ref-type="bibr" href="#ref12">12</a><a class="xref" ref-type="bibr" href="#ref13">13</a> To date, the association between dipeptidyl peptidase-4 enzyme concentrations and
                  incident inflammatory bowel disease has not been studied.
               </p>
               <p class="p">To our knowledge, no observational study has specifically investigated the association
                  between use of dipeptidyl peptidase-4 inhibitors and the incidence of inflammatory
                  bowel disease. Thus, the objective of this population based study was to determine
                  whether the use of dipeptidyl peptidase-4 inhibitors is associated with the incidence
                  of inflammatory bowel disease in patients with type 2 diabetes.
               </p>
            </div>
            <div class="sec methods">
               <div class="title" id="Methods">Methods</div>
               <div class="sec">
                  <div class="title" id="Data source">Data source</div>
                  <p class="p">This study used data from the Clinical Practice Research Datalink (CPRD), a primary
                     care database from the UK. The CPRD records demographic and lifestyle information,
                     prescription data, referrals, and diagnoses for more than 15 million patients in more
                     than 700 general practices. These data are representative of the general UK population
                     and have been shown to be of high quality and validity.<a class="xref" ref-type="bibr" href="#ref14">14</a><a class="xref" ref-type="bibr" href="#ref15">15</a><a class="xref" ref-type="bibr" href="#ref16">16</a> The CPRD uses the Read code classification for medical diagnoses and procedures,<a class="xref" ref-type="bibr" href="#ref17">17</a> and a coded drug dictionary based on the <i class="italic">British National Formulary</i> for prescription details.
                  </p>
               </div>
               <div class="sec">
                  <div class="title" id="Study population">Study population</div>
                  <p class="p">We identified a base cohort of patients, at least 18 years of age, newly treated with
                     non-insulin antidiabetic drugs (metformin, sulfonylureas, meglitinides, thiazolidinediones,
                     acarbose, dipeptidyl peptidase-4 inhibitors, glucagon-like peptide 1 receptor agonists,
                     and sodium-glucose co-transporter-2 inhibitors) between 1 January 1988 and 31 December
                     2016. Patients were required to have at least one year of medical history in the CPRD
                     before their initial prescription. We excluded patients treated with insulin at any
                     time before their initial prescription for a non-insulin antidiabetic drug (that is,
                     patients with advanced disease) and female patients with a history of polycystic ovary
                     syndrome (at any time before their initial prescription) or a history of gestational
                     diabetes (in the year before their initial prescription), as these are other indications
                     for metformin.
                  </p>
                  <p class="p">Within the base cohort, we assembled a study cohort of patients who started a new
                     antidiabetic drug class not previously used in their treatment history in or after
                     2007 (the year the first dipeptidyl peptidase-4 inhibitor, sitagliptin, entered the
                     UK market).<a class="xref" ref-type="bibr" href="#ref3">3</a> This cohort thus included patients newly treated for diabetes, as well as those for
                     whom treatment was newly modified (add-ons or switches). Cohort entry was the date
                     of this new antidiabetic prescription. At this stage, we excluded patients previously
                     diagnosed as having inflammatory bowel disease, including those previously exposed
                     to mesalamine, at any time before cohort entry (Crohn’s disease and ulcerative colitis;
                     Read codes listed in supplementary table A). Diagnoses of inflammatory bowel disease
                     have been previously validated in the CPRD, with positive predictive values above
                     90%.<a class="xref" ref-type="bibr" href="#ref18">18</a><a class="xref" ref-type="bibr" href="#ref19">19</a><a class="xref" ref-type="bibr" href="#ref20">20</a> We also excluded patients with a history of diverticulitis, ischaemic colitis, pseudomembranous
                     colitis, or unspecific colitis (common differential diagnoses for inflammatory bowel
                     disease<a class="xref" ref-type="bibr" href="#ref21">21</a>) at any time before cohort entry. Finally, we excluded patients with less than six
                     months of follow-up after cohort entry to account for a latency period and known diagnostic
                     delays of inflammatory bowel disease.<a class="xref" ref-type="bibr" href="#ref22">22</a> All patients were followed starting six months after cohort entry until an incident
                     diagnosis of inflammatory bowel disease or censored on an incident diagnosis of ischaemic
                     colitis or diverticulitis, death from any cause, end of registration with the general
                     practice, or the end of the study period (30 June 2017), whichever occurred first.
                  </p>
               </div>
               <div class="sec">
                  <div class="title" id="Exposure assessment">Exposure assessment</div>
                  <p class="p">We modelled the use of dipeptidyl peptidase-4 inhibitors (alone or in combination
                     with other antidiabetic drugs) as a time varying variable and compared it with the
                     use of all other antidiabetic drugs. As part of this exposure definition, patients
                     could move from a period of non-exposure to a period of exposure after a six month
                     lag period (allowing them to contribute both unexposed and exposed person time). Thus,
                     patients were considered exposed starting six months after their first prescription
                     until the end of the follow-up period, analogous to an intention to treat approach.
                     Consequently, we considered inflammatory bowel disease events occurring during the
                     six month lag period to be unexposed events. The use of a lag period was necessary
                     for latency considerations, given that exposures of short duration are unlikely to
                     be associated with the incidence of inflammatory bowel disease, to account for possible
                     diagnostic delays associated with inflammatory bowel disease,<a class="xref" ref-type="bibr" href="#ref22">22</a> and to reduce detection bias and reverse causality. Finally, we deemed the comparator
                     group of other antidiabetic drugs to be appropriate, as none of these drugs has been
                     previously associated with the incidence of inflammatory bowel disease. We considered
                     this to be the definition of primary exposure.
                  </p>
                  <p class="p">We also considered two definitions of secondary exposure. The first assessed the association
                     according to cumulative duration of dipeptidyl peptidase-4 inhibitor use. We defined
                     this time dependent variable by summing the durations associated with each prescription
                     up until time of event. The second assessed time since initiation, which we defined
                     in a time dependent fashion as the time between the first dipeptidyl peptidase-4 inhibitor
                     prescription and time of event.
                  </p>
               </div>
               <div class="sec">
                  <div class="title" id="Potential confounders">Potential confounders</div>
                  <p class="p">The models were adjusted for the following potential confounders measured at cohort
                     entry: age, sex, year of cohort entry, body mass index, alcohol related disorders
                     (alcoholism, alcoholic cirrhosis of the liver, alcoholic hepatitis, and hepatic failure),
                     and smoking status. We also adjusted for haemoglobin A<sub class="sub">1c</sub> (last laboratory result before cohort entry), microvascular (nephropathy, neuropathy,
                     retinopathy) and macrovascular (myocardial infarction, stroke, peripheral arteriopathy)
                     complications of diabetes (at any time before cohort entry), duration of treated diabetes,
                     and antidiabetic drugs used before cohort entry, as proxies for disease severity.
                     Age and duration of treated diabetes were modelled flexibly as continuous variables
                     by using cubic spline models to account for possible non-linear relations with the
                     outcome. The models also considered the use of aspirin, non-steroidal anti-inflammatory
                     drugs, hormonal replacement therapy, oral contraceptives, other autoimmune conditions
                     (all at any time before cohort entry),<a class="xref" ref-type="bibr" href="#ref23">23</a> as well as the total number of unique non-antidiabetic drugs received in the year
                     before cohort entry as a general measure of comorbidity.<a class="xref" ref-type="bibr" href="#ref24">24</a></p>
               </div>
               <div class="sec">
                  <div class="title" id="Statistical analysis">Statistical analysis</div>
                  <p class="p">We calculated crude incidence rates of inflammatory bowel disease with 95% confidence
                     intervals based on the Poisson distribution for the entire cohort and for each exposure
                     group. For all analyses, we used time dependent Cox proportional hazards models to
                     estimate hazard ratios and 95% confidence intervals for inflammatory bowel disease
                     associated with the use of dipeptidyl peptidase-4 inhibitors compared with the use
                     of other antidiabetic drugs. The models were adjusted for the potential confounders
                     listed above. We also calculated the number needed to harm for patients followed over
                     a two year and four year period by using methods accounting for varying patient follow-up
                     times.<a class="xref" ref-type="bibr" href="#ref25">25</a></p>
                  <div class="sec">
                     <div class="title" id="Secondary analyses">Secondary analyses</div>
                     <p class="p">We did four secondary analyses. Firstly, we assessed whether a duration-response relation
                        existed according to cumulative duration of use by estimating hazard ratios for five
                        predefined duration categories (≤1 year, 1.1-2 years, 2.1-3 years, 3.1-4 years, and
                        &gt;4 years). Secondly, we investigated the association with time since initiation by
                        estimating hazard ratios for three predefined categories (≤2 years, 2.1-4 years, and
                        &gt;4 years). We also modelled cumulative duration of use and time since initiation as
                        continuous variables by using restricted cubic splines. Thirdly, to investigate the
                        possibility of a drug specific effect, we repeated the analysis stratifying by type
                        of dipeptidyl peptidase-4 inhibitor (sitagliptin, saxagliptin, and other). Finally,
                        we repeated the primary analysis by stratifying on type of inflammatory bowel disease
                        (Crohn’s disease, ulcerative colitis, and unspecified disease).
                     </p>
                  </div>
                  <div class="sec">
                     <div class="title" id="Sensitivity analyses">Sensitivity analyses</div>
                     <p class="p">We did 11 sensitivity analyses to assess the robustness of our findings. Firstly,
                        given uncertainties related to the length of the lag period, we increased the exposure
                        lag period to one year. Secondly, to assess the validity of our outcome definition,
                        we restricted inflammatory bowel disease events to those accompanied by clinically
                        relevant supporting events (supplementary methods 1). Thirdly, to investigate the
                        effect of informative censoring, we did a competing risk analysis by death from any
                        cause, using the Fine and Gray subdistribution model.<a class="xref" ref-type="bibr" href="#ref26">26</a> Fourthly, to investigate the effect of detection bias from undiagnosed inflammatory
                        bowel disease, we stratified the cohort by age at cohort entry (&lt;60 and ≥60 years).
                        In the UK, patients aged 60-74 years are invited for faecal occult blood tests every
                        two years as part of the Bowel Cancer Screening Programme.<a class="xref" ref-type="bibr" href="#ref27">27</a> Fifthly, we used a stricter exposure definition, in which dipeptidyl peptidase-4
                        inhibitor use was redefined as receipt of at least four prescriptions within a 12
                        month moving window; we considered patients to be exposed only six months after the
                        fourth qualifying prescription. Sixthly, to account for a possible incretin effect
                        of glucagon-like peptide 1 receptor agonists, we redefined exposure into four mutually
                        exclusive categories: dipeptidyl peptidase-4 inhibitors (alone or in combination,
                        excluding glucagon-like peptide 1 receptor agonists), glucagon-like peptide 1 receptor
                        agonists (alone or in combination, excluding dipeptidyl peptidase-4 inhibitors), both
                        dipeptidyl peptidase-4 inhibitor and glucagon-like peptide 1 receptor agonists, and
                        other antidiabetic drugs (new reference category). Seventhly, to assess the possibility
                        of anti-inflammatory effects of thiazolidinediones,<a class="xref" ref-type="bibr" href="#ref28">28</a> we excluded patients treated with thiazolidinediones at any time before cohort entry
                        and censored them on initiation during follow-up. The eighth to tenth analyses assessed
                        the effect of residual confounding by conducting a marginal structural model (using
                        inverse probability of treatment and censoring weighting), disease risk score, and
                        multiple imputation for variables with missing information (supplementary methods
                        2-4). Finally, in a post hoc sensitivity analysis, we used the rule out method to
                        estimate the strength of an unknown or unmeasured confounder that would be needed
                        to move the observed hazard ratio to the null.<a class="xref" ref-type="bibr" href="#ref29">29</a></p>
                  </div>
                  <div class="sec">
                     <div class="title" id="Ancillary analyses">Ancillary analyses</div>
                     <p class="p">We did two ancillary analyses to further assess the validity of our findings. The
                        first used insulin as a negative control exposure,<a class="xref" ref-type="bibr" href="#ref30">30</a> a last line treatment that has not been associated with inflammatory bowel disease.
                        For this analysis, we excluded prevalent users of insulin before cohort entry and
                        modelled new use of insulin as a time dependent variable lagged by six months. The
                        second was a head to head comparison of patients newly treated with dipeptidyl peptidase-4
                        inhibitors versus insulin between 1 January 2007 and 31 December 2016, with follow-up
                        until 30 June 2017. For this analysis, a Cox proportional hazard model was stratified
                        on fifths of propensity score (supplementary methods 5). We used SAS version 9.4 for
                        all the analyses described above.
                     </p>
                  </div>
               </div>
               <div class="sec">
                  <div class="title" id="Patient involvement">Patient involvement</div>
                  <p class="p">We did not include patients as study participants, as our study involved the use of
                     secondary data. Patients were not involved in the design or implementation of the
                     study. We do not plan to involve patients in the dissemination of results, nor will
                     we disseminate results directly to patients.
                  </p>
               </div>
            </div>
            <div class="sec results">
               <div class="title" id="Results">Results</div>
               <p class="p">We included 141 170 patients in the cohort (<a class="xref" ref-type="fig" href="#f1">fig 1</a>). These patients were followed for a median of 3.6 (interquartile range 1.6-5.9)
                  years beyond the six month post-cohort entry lag period. During 552 413 person years
                  of follow-up, 208 incident inflammatory bowel disease events occurred, generating
                  an incidence rate of 37.7 (95% confidence interval 32.7 to 43.1) per 100 000 person
                  years. Nearly all these events (n=193; 92.8%) had at least one clinically relevant
                  supporting event (supplementary table B). Overall, 30 488 (21.6%) patients received
                  at least one prescription for a dipeptidyl peptidase-4 inhibitor during the study
                  period; the median duration of use was 1.6 (interquartile range 0.7-3.1) years.
               </p>
               <div id="f1" class="fig f1 float figure"><span class="label">Fig 1</span><div class="caption">
                     <p class="p">Flowchart of patients included in base and study cohorts</p>
                  </div><img src="graphics\abrd041828.f1.jpg"></div>
               <p class="p"><a class="xref" ref-type="table" href="#tbl1">Table 1</a> shows the baseline characteristics of the entire cohort and the cohort stratified
                  by drug use at cohort entry. Compared with users of other antidiabetic drugs, dipeptidyl
                  peptidase-4 inhibitor users were older, more likely to have higher haemoglobin A<sub class="sub">1c</sub> concentrations, more likely to have a longer duration of treated diabetes, and more
                  likely to have microvascular complications of diabetes. Users of dipeptidyl peptidase-4
                  inhibitors were also more likely to have used aspirin and non-steroidal anti-inflammatory
                  drugs but less likely to have used oral contraceptives.
               </p>
               <div class="clickForTable"><b><a id="tbl1" href="#openModal1">Table&nbsp;1</a></b><div id="openModal1" class="modalDialog">
                     <div><span class="label">Table 1</span><div class="caption">
                           <p class="p">Baseline characteristics of entire cohort and cohort stratified by drug use at cohort
                              entry. Values are numbers (percentages) unless stated otherwise
                           </p>
                        </div>
                        <div class="modalWindow"><a href="#close" title="Close" class="close">X</a><table class="modalTable" frame="above" rules="groups">
                              <col width="50.51%">
                              <col width="12.96%">
                              <col width="15.13%">
                              <col width="21.4%">
                              <thead>
                                 <tr>
                                    <th rowspan="2" valign="bottom" align="left" scope="col" colspan="1">Characteristic</th>
                                    <th rowspan="2" valign="bottom" align="center" scope="col" colspan="1">Entire cohort (n=141 170)</th>
                                    <th valign="bottom" colspan="2" align="center" scope="colgroup" rowspan="1">Use at cohort entry</th>
                                 </tr>
                                 <tr>
                                    <th valign="bottom" colspan="1" align="center" scope="colgroup" rowspan="1">DPP-4 inhibitors (n=7231)</th>
                                    <th valign="bottom" align="center" scope="col" colspan="1" rowspan="1">Other antidiabetic drugs (n=133 939)</th>
                                 </tr>
                              </thead>
                              <tbody>
                                 <tr>
                                    <td valign="top" align="left" scope="row" colspan="1" rowspan="1">Mean (SD) age, years</td>
                                    <td valign="top" align="center" colspan="1" rowspan="1">61.6 (13.6)</td>
                                    <td valign="top" align="center" colspan="1" rowspan="1">66.1 (11.8)</td>
                                    <td valign="top" align="center" colspan="1" rowspan="1">61.4 (13.6)</td>
                                 </tr>
                                 <tr>
                                    <td valign="top" align="left" scope="row" colspan="1" rowspan="1">Male sex</td>
                                    <td valign="top" align="center" colspan="1" rowspan="1">80 995 (57.4)</td>
                                    <td valign="top" align="center" colspan="1" rowspan="1">4164 (57.6)</td>
                                    <td valign="top" align="center" colspan="1" rowspan="1">76 831 (57.4)</td>
                                 </tr>
                                 <tr>
                                    <td valign="top" align="left" scope="col" colspan="1" rowspan="1">Year of cohort entry:</td>
                                    <td valign="top" align="left" colspan="1" rowspan="1"></td>
                                    <td valign="top" align="left" colspan="1" rowspan="1"></td>
                                    <td valign="top" align="left" colspan="1" rowspan="1"></td>
                                 </tr>
                                 <tr>
                                    <td valign="top" align="left" scope="row" colspan="1" rowspan="1"> 2007</td>
                                    <td valign="top" align="center" colspan="1" rowspan="1">20 368 (14.4)</td>
                                    <td valign="top" align="center" colspan="1" rowspan="1">126 (1.7)</td>
                                    <td valign="top" align="center" colspan="1" rowspan="1">20 242 (15.1)</td>
                                 </tr>
                                 <tr>
                                    <td valign="top" align="left" scope="row" colspan="1" rowspan="1"> 2008</td>
                                    <td valign="top" align="center" colspan="1" rowspan="1">18 658 (13.2)</td>
                                    <td valign="top" align="center" colspan="1" rowspan="1">506 (7.0)</td>
                                    <td valign="top" align="center" colspan="1" rowspan="1">18 152 (13.6)</td>
                                 </tr>
                                 <tr>
                                    <td valign="top" align="left" scope="row" colspan="1" rowspan="1"> 2009</td>
                                    <td valign="top" align="center" colspan="1" rowspan="1">18 801 (13.3)</td>
                                    <td valign="top" align="center" colspan="1" rowspan="1">1014 (14.0)</td>
                                    <td valign="top" align="center" colspan="1" rowspan="1">17 787 (13.3)</td>
                                 </tr>
                                 <tr>
                                    <td valign="top" align="left" scope="row" colspan="1" rowspan="1"> 2010</td>
                                    <td valign="top" align="center" colspan="1" rowspan="1">17 507 (12.4)</td>
                                    <td valign="top" align="center" colspan="1" rowspan="1">1485 (20.5)</td>
                                    <td valign="top" align="center" colspan="1" rowspan="1">16 022 (12.0)</td>
                                 </tr>
                                 <tr>
                                    <td valign="top" align="left" scope="row" colspan="1" rowspan="1"> 2011</td>
                                    <td valign="top" align="center" colspan="1" rowspan="1">14 701 (10.4)</td>
                                    <td valign="top" align="center" colspan="1" rowspan="1">1103 (15.3)</td>
                                    <td valign="top" align="center" colspan="1" rowspan="1">13 598 (10.2)</td>
                                 </tr>
                                 <tr>
                                    <td valign="top" align="left" scope="row" colspan="1" rowspan="1"> 2012</td>
                                    <td valign="top" align="center" colspan="1" rowspan="1">13 788 (9.8)</td>
                                    <td valign="top" align="center" colspan="1" rowspan="1">983 (13.6)</td>
                                    <td valign="top" align="center" colspan="1" rowspan="1">12 805 (9.6)</td>
                                 </tr>
                                 <tr>
                                    <td valign="top" align="left" scope="row" colspan="1" rowspan="1"> 2013</td>
                                    <td valign="top" align="center" colspan="1" rowspan="1">12 214 (8.7)</td>
                                    <td valign="top" align="center" colspan="1" rowspan="1">744 (10.3)</td>
                                    <td valign="top" align="center" colspan="1" rowspan="1">11 470 (8.6)</td>
                                 </tr>
                                 <tr>
                                    <td valign="top" align="left" scope="row" colspan="1" rowspan="1"> 2014</td>
                                    <td valign="top" align="center" colspan="1" rowspan="1">9896 (7.0)</td>
                                    <td valign="top" align="center" colspan="1" rowspan="1">544 (7.5)</td>
                                    <td valign="top" align="center" colspan="1" rowspan="1">9352 (7.0)</td>
                                 </tr>
                                 <tr>
                                    <td valign="top" align="left" scope="row" colspan="1" rowspan="1"> 2015</td>
                                    <td valign="top" align="center" colspan="1" rowspan="1">8731 (6.2)</td>
                                    <td valign="top" align="center" colspan="1" rowspan="1">451 (6.2)</td>
                                    <td valign="top" align="center" colspan="1" rowspan="1">8280 (6.2)</td>
                                 </tr>
                                 <tr>
                                    <td valign="top" align="left" scope="row" colspan="1" rowspan="1"> 2016</td>
                                    <td valign="top" align="center" colspan="1" rowspan="1">6506 (4.6)</td>
                                    <td valign="top" align="center" colspan="1" rowspan="1">275 (3.8)</td>
                                    <td valign="top" align="center" colspan="1" rowspan="1">6231 (4.7)</td>
                                 </tr>
                                 <tr>
                                    <td valign="top" align="left" scope="col" colspan="1" rowspan="1">Body mass index:</td>
                                    <td valign="top" align="left" colspan="1" rowspan="1"></td>
                                    <td valign="top" align="left" colspan="1" rowspan="1"></td>
                                    <td valign="top" align="left" colspan="1" rowspan="1"></td>
                                 </tr>
                                 <tr>
                                    <td valign="top" align="left" scope="row" colspan="1" rowspan="1"> &lt;25</td>
                                    <td valign="top" align="center" colspan="1" rowspan="1">14 743 (10.4)</td>
                                    <td valign="top" align="center" colspan="1" rowspan="1">736 (10.2)</td>
                                    <td valign="top" align="center" colspan="1" rowspan="1">14 007 (10.5)</td>
                                 </tr>
                                 <tr>
                                    <td valign="top" align="left" scope="row" colspan="1" rowspan="1"> 25-30</td>
                                    <td valign="top" align="center" colspan="1" rowspan="1">41 434 (29.4)</td>
                                    <td valign="top" align="center" colspan="1" rowspan="1">2127 (29.4)</td>
                                    <td valign="top" align="center" colspan="1" rowspan="1">39 307 (29.3)</td>
                                 </tr>
                                 <tr>
                                    <td valign="top" align="left" scope="row" colspan="1" rowspan="1"> ≥30</td>
                                    <td valign="top" align="center" colspan="1" rowspan="1">81 993 (58.1)</td>
                                    <td valign="top" align="center" colspan="1" rowspan="1">4337 (60.0)</td>
                                    <td valign="top" align="center" colspan="1" rowspan="1">77 656 (58.0)</td>
                                 </tr>
                                 <tr>
                                    <td valign="top" align="left" scope="row" colspan="1" rowspan="1"> Unknown</td>
                                    <td valign="top" align="center" colspan="1" rowspan="1">3000 (2.1)</td>
                                    <td valign="top" align="center" colspan="1" rowspan="1">31 (0.4)</td>
                                    <td valign="top" align="center" colspan="1" rowspan="1">2969 (2.2)</td>
                                 </tr>
                                 <tr>
                                    <td valign="top" align="left" scope="row" colspan="1" rowspan="1">Alcohol related disorders</td>
                                    <td valign="top" align="center" colspan="1" rowspan="1">20 782 (14.7)</td>
                                    <td valign="top" align="center" colspan="1" rowspan="1">1431 (19.8)</td>
                                    <td valign="top" align="center" colspan="1" rowspan="1">19 351 (14.5)</td>
                                 </tr>
                                 <tr>
                                    <td valign="top" align="left" scope="col" colspan="1" rowspan="1">Smoking status:</td>
                                    <td valign="top" align="left" colspan="1" rowspan="1"></td>
                                    <td valign="top" align="left" colspan="1" rowspan="1"></td>
                                    <td valign="top" align="left" colspan="1" rowspan="1"></td>
                                 </tr>
                                 <tr>
                                    <td valign="top" align="left" scope="row" colspan="1" rowspan="1"> Current smoker</td>
                                    <td valign="top" align="center" colspan="1" rowspan="1">22 812 (16.2)</td>
                                    <td valign="top" align="center" colspan="1" rowspan="1">940 (13.0)</td>
                                    <td valign="top" align="center" colspan="1" rowspan="1">21 872 (16.3)</td>
                                 </tr>
                                 <tr>
                                    <td valign="top" align="left" scope="row" colspan="1" rowspan="1"> Past smoker</td>
                                    <td valign="top" align="center" colspan="1" rowspan="1">51 490 (36.5)</td>
                                    <td valign="top" align="center" colspan="1" rowspan="1">2817 (39.0)</td>
                                    <td valign="top" align="center" colspan="1" rowspan="1">48 673 (36.3)</td>
                                 </tr>
                                 <tr>
                                    <td valign="top" align="left" scope="row" colspan="1" rowspan="1"> Never smoker</td>
                                    <td valign="top" align="center" colspan="1" rowspan="1">66 350 (47.0)</td>
                                    <td valign="top" align="center" colspan="1" rowspan="1">3467 (47.9)</td>
                                    <td valign="top" align="center" colspan="1" rowspan="1">62 883 (47.0)</td>
                                 </tr>
                                 <tr>
                                    <td valign="top" align="left" scope="row" colspan="1" rowspan="1"> Unknown</td>
                                    <td valign="top" align="center" colspan="1" rowspan="1">518 (0.4)</td>
                                    <td valign="top" align="center" colspan="1" rowspan="1">7 (0.1)</td>
                                    <td valign="top" align="center" colspan="1" rowspan="1">511 (0.4)</td>
                                 </tr>
                                 <tr>
                                    <td valign="top" align="left" scope="col" colspan="1" rowspan="1">Haemoglobin A<sub class="sub">1c</sub>:
                                    </td>
                                    <td valign="top" align="left" colspan="1" rowspan="1"></td>
                                    <td valign="top" align="left" colspan="1" rowspan="1"></td>
                                    <td valign="top" align="left" colspan="1" rowspan="1"></td>
                                 </tr>
                                 <tr>
                                    <td valign="top" align="left" scope="row" colspan="1" rowspan="1"> ≤7.0%</td>
                                    <td valign="top" align="center" colspan="1" rowspan="1">25 508 (18.1)</td>
                                    <td valign="top" align="center" colspan="1" rowspan="1">1325 (18.3)</td>
                                    <td valign="top" align="center" colspan="1" rowspan="1">24 183 (18.1)</td>
                                 </tr>
                                 <tr>
                                    <td valign="top" align="left" scope="row" colspan="1" rowspan="1"> 7.1-8.0%</td>
                                    <td valign="top" align="center" colspan="1" rowspan="1">30 720 (21.8)</td>
                                    <td valign="top" align="center" colspan="1" rowspan="1">2424 (33.5)</td>
                                    <td valign="top" align="center" colspan="1" rowspan="1">28 296 (21.1)</td>
                                 </tr>
                                 <tr>
                                    <td valign="top" align="left" scope="row" colspan="1" rowspan="1"> &gt;8.0%</td>
                                    <td valign="top" align="center" colspan="1" rowspan="1">43 227 (30.6)</td>
                                    <td valign="top" align="center" colspan="1" rowspan="1">3170 (43.8)</td>
                                    <td valign="top" align="center" colspan="1" rowspan="1">40 057 (29.9)</td>
                                 </tr>
                                 <tr>
                                    <td valign="top" align="left" scope="row" colspan="1" rowspan="1"> Unknown</td>
                                    <td valign="top" align="center" colspan="1" rowspan="1">41 715 (29.6)</td>
                                    <td valign="top" align="center" colspan="1" rowspan="1">312 (4.3)</td>
                                    <td valign="top" align="center" colspan="1" rowspan="1">41 403 (30.9)</td>
                                 </tr>
                                 <tr>
                                    <td valign="top" align="left" scope="row" colspan="1" rowspan="1">Nephropathy</td>
                                    <td valign="top" align="center" colspan="1" rowspan="1">34 573 (24.5)</td>
                                    <td valign="top" align="center" colspan="1" rowspan="1">2855 (39.5)</td>
                                    <td valign="top" align="center" colspan="1" rowspan="1">31 718 (23.7)</td>
                                 </tr>
                                 <tr>
                                    <td valign="top" align="left" scope="row" colspan="1" rowspan="1">Neuropathy</td>
                                    <td valign="top" align="center" colspan="1" rowspan="1">14 564 (10.3)</td>
                                    <td valign="top" align="center" colspan="1" rowspan="1">1838 (25.4)</td>
                                    <td valign="top" align="center" colspan="1" rowspan="1">12 726 (9.5)</td>
                                 </tr>
                                 <tr>
                                    <td valign="top" align="left" scope="row" colspan="1" rowspan="1">Retinopathy</td>
                                    <td valign="top" align="center" colspan="1" rowspan="1">15 249 (10.8)</td>
                                    <td valign="top" align="center" colspan="1" rowspan="1">2348 (32.5)</td>
                                    <td valign="top" align="center" colspan="1" rowspan="1">12 901 (9.6)</td>
                                 </tr>
                                 <tr>
                                    <td valign="top" align="left" scope="row" colspan="1" rowspan="1">Myocardial infarction</td>
                                    <td valign="top" align="center" colspan="1" rowspan="1">9627 (6.8)</td>
                                    <td valign="top" align="center" colspan="1" rowspan="1">598 (8.3)</td>
                                    <td valign="top" align="center" colspan="1" rowspan="1">9029 (6.7)</td>
                                 </tr>
                                 <tr>
                                    <td valign="top" align="left" scope="row" colspan="1" rowspan="1">Stroke</td>
                                    <td valign="top" align="center" colspan="1" rowspan="1">6844 (4.9)</td>
                                    <td valign="top" align="center" colspan="1" rowspan="1">463 (6.4)</td>
                                    <td valign="top" align="center" colspan="1" rowspan="1">6381 (4.8)</td>
                                 </tr>
                                 <tr>
                                    <td valign="top" align="left" scope="row" colspan="1" rowspan="1">Peripheral arteriopathy</td>
                                    <td valign="top" align="center" colspan="1" rowspan="1">5010 (3.6)</td>
                                    <td valign="top" align="center" colspan="1" rowspan="1">417 (5.8)</td>
                                    <td valign="top" align="center" colspan="1" rowspan="1">4593 (3.4)</td>
                                 </tr>
                                 <tr>
                                    <td valign="top" align="left" scope="row" colspan="1" rowspan="1">Mean (SD) duration of treated diabetes, years</td>
                                    <td valign="top" align="center" colspan="1" rowspan="1">1.3 (3.0)</td>
                                    <td valign="top" align="center" colspan="1" rowspan="1">7.7 (4.2)</td>
                                    <td valign="top" align="center" colspan="1" rowspan="1">1.0 (2.5)</td>
                                 </tr>
                                 <tr>
                                    <td valign="top" align="left" scope="col" colspan="1" rowspan="1">Class of antidiabetic drugs<a class="xref" ref-type="table-fn" href="#t1n1">*</a>:
                                    </td>
                                    <td valign="top" align="left" colspan="1" rowspan="1"></td>
                                    <td valign="top" align="left" colspan="1" rowspan="1"></td>
                                    <td valign="top" align="left" colspan="1" rowspan="1"></td>
                                 </tr>
                                 <tr>
                                    <td valign="top" align="left" scope="row" colspan="1" rowspan="1"> Metformin</td>
                                    <td valign="top" align="center" colspan="1" rowspan="1">27 265 (19.3)</td>
                                    <td valign="top" align="center" colspan="1" rowspan="1">6482 (89.6)</td>
                                    <td valign="top" align="center" colspan="1" rowspan="1">20 783 (15.5)</td>
                                 </tr>
                                 <tr>
                                    <td valign="top" align="left" scope="row" colspan="1" rowspan="1"> Sulfonylureas</td>
                                    <td valign="top" align="center" colspan="1" rowspan="1">13 522 (9.6)</td>
                                    <td valign="top" align="center" colspan="1" rowspan="1">4032 (55.8)</td>
                                    <td valign="top" align="center" colspan="1" rowspan="1">9490 (7.1)</td>
                                 </tr>
                                 <tr>
                                    <td valign="top" align="left" scope="row" colspan="1" rowspan="1"> Thiazolidinediones</td>
                                    <td valign="top" align="center" colspan="1" rowspan="1">7154 (5.1)</td>
                                    <td valign="top" align="center" colspan="1" rowspan="1">2462 (34.1)</td>
                                    <td valign="top" align="center" colspan="1" rowspan="1">4692 (3.5)</td>
                                 </tr>
                                 <tr>
                                    <td valign="top" align="left" scope="row" colspan="1" rowspan="1"> Insulin</td>
                                    <td valign="top" align="center" colspan="1" rowspan="1">1213 (0.9)</td>
                                    <td valign="top" align="center" colspan="1" rowspan="1">373 (5.2)</td>
                                    <td valign="top" align="center" colspan="1" rowspan="1">840 (0.6)</td>
                                 </tr>
                                 <tr>
                                    <td valign="top" align="left" scope="row" colspan="1" rowspan="1"> Other</td>
                                    <td valign="top" align="center" colspan="1" rowspan="1">939 (0.7)</td>
                                    <td valign="top" align="center" colspan="1" rowspan="1">277 (3.8)</td>
                                    <td valign="top" align="center" colspan="1" rowspan="1">662 (0.5)</td>
                                 </tr>
                                 <tr>
                                    <td valign="top" align="left" scope="row" colspan="1" rowspan="1">Aspirin</td>
                                    <td valign="top" align="center" colspan="1" rowspan="1">60 329 (42.7)</td>
                                    <td valign="top" align="center" colspan="1" rowspan="1">4760 (65.8)</td>
                                    <td valign="top" align="center" colspan="1" rowspan="1">55 569 (41.5)</td>
                                 </tr>
                                 <tr>
                                    <td valign="top" align="left" scope="row" colspan="1" rowspan="1">Non-steroidal anti-inflammatory drugs</td>
                                    <td valign="top" align="center" colspan="1" rowspan="1">76 366 (54.1)</td>
                                    <td valign="top" align="center" colspan="1" rowspan="1">4600 (63.6)</td>
                                    <td valign="top" align="center" colspan="1" rowspan="1">71 766 (53.6)</td>
                                 </tr>
                                 <tr>
                                    <td valign="top" align="left" scope="row" colspan="1" rowspan="1">Hormonal replacement therapy</td>
                                    <td valign="top" align="center" colspan="1" rowspan="1">17 202 (12.2)</td>
                                    <td valign="top" align="center" colspan="1" rowspan="1">1069 (14.8)</td>
                                    <td valign="top" align="center" colspan="1" rowspan="1">16 133 (12.1)</td>
                                 </tr>
                                 <tr>
                                    <td valign="top" align="left" scope="row" colspan="1" rowspan="1">Oral contraceptives</td>
                                    <td valign="top" align="center" colspan="1" rowspan="1">11 567 (8.2)</td>
                                    <td valign="top" align="center" colspan="1" rowspan="1">398 (5.5)</td>
                                    <td valign="top" align="center" colspan="1" rowspan="1">11 169 (8.3)</td>
                                 </tr>
                                 <tr>
                                    <td valign="top" align="left" scope="row" colspan="1" rowspan="1">Other autoimmune conditions:</td>
                                    <td valign="top" align="center" colspan="1" rowspan="1">4418 (3.1)</td>
                                    <td valign="top" align="center" colspan="1" rowspan="1">250 (3.5)</td>
                                    <td valign="top" align="center" colspan="1" rowspan="1">4168 (3.1)</td>
                                 </tr>
                                 <tr>
                                    <td valign="top" align="left" scope="row" colspan="1" rowspan="1"> Psoriasis</td>
                                    <td valign="top" align="center" colspan="1" rowspan="1">1821 (1.3)</td>
                                    <td valign="top" align="center" colspan="1" rowspan="1">92 (1.3)</td>
                                    <td valign="top" align="center" colspan="1" rowspan="1">1729 (1.3)</td>
                                 </tr>
                                 <tr>
                                    <td valign="top" align="left" scope="row" colspan="1" rowspan="1"> Systemic vasculitis</td>
                                    <td valign="top" align="center" colspan="1" rowspan="1">513 (0.4)</td>
                                    <td valign="top" align="center" colspan="1" rowspan="1">18 (0.3)</td>
                                    <td valign="top" align="center" colspan="1" rowspan="1">495 (0.4)</td>
                                 </tr>
                                 <tr>
                                    <td valign="top" align="left" scope="row" colspan="1" rowspan="1"> Rheumatoid arthritis</td>
                                    <td valign="top" align="center" colspan="1" rowspan="1">1953 (1.4)</td>
                                    <td valign="top" align="center" colspan="1" rowspan="1">123 (1.7)</td>
                                    <td valign="top" align="center" colspan="1" rowspan="1">1830 (1.4)</td>
                                 </tr>
                                 <tr>
                                    <td valign="top" align="left" scope="row" colspan="1" rowspan="1"> Sjögren’s syndrome</td>
                                    <td valign="top" align="center" colspan="1" rowspan="1">161 (0.1)</td>
                                    <td valign="top" align="center" colspan="1" rowspan="1">14 (0.2)</td>
                                    <td valign="top" align="center" colspan="1" rowspan="1">147 (0.1)</td>
                                 </tr>
                                 <tr>
                                    <td valign="top" align="left" scope="row" colspan="1" rowspan="1"> Systemic lupus erythematosus</td>
                                    <td valign="top" align="center" colspan="1" rowspan="1">166 (0.1)</td>
                                    <td valign="top" align="center" colspan="1" rowspan="1">11 (0.2)</td>
                                    <td valign="top" align="center" colspan="1" rowspan="1">155 (0.1)</td>
                                 </tr>
                                 <tr>
                                    <td valign="top" align="left" scope="col" colspan="1" rowspan="1">No of non-antidiabetic drugs:</td>
                                    <td valign="top" align="left" colspan="1" rowspan="1"></td>
                                    <td valign="top" align="left" colspan="1" rowspan="1"></td>
                                    <td valign="top" align="left" colspan="1" rowspan="1"></td>
                                 </tr>
                                 <tr>
                                    <td valign="top" align="left" scope="row" colspan="1" rowspan="1"> Mean (SD)</td>
                                    <td valign="top" align="center" colspan="1" rowspan="1">8.2 (6.1)</td>
                                    <td valign="top" align="center" colspan="1" rowspan="1">10.5 (6.3)</td>
                                    <td valign="top" align="center" colspan="1" rowspan="1">8.0 (6.0)</td>
                                 </tr>
                                 <tr>
                                    <td valign="top" align="left" scope="row" colspan="1" rowspan="1"> 0</td>
                                    <td valign="top" align="center" colspan="1" rowspan="1">6206 (4.4)</td>
                                    <td valign="top" align="center" colspan="1" rowspan="1">59 (0.8)</td>
                                    <td valign="top" align="center" colspan="1" rowspan="1">6147 (4.6)</td>
                                 </tr>
                                 <tr>
                                    <td valign="top" align="left" scope="row" colspan="1" rowspan="1"> 1</td>
                                    <td valign="top" align="center" colspan="1" rowspan="1">7228 (5.1)</td>
                                    <td valign="top" align="center" colspan="1" rowspan="1">103 (1.4)</td>
                                    <td valign="top" align="center" colspan="1" rowspan="1">7125 (5.3)</td>
                                 </tr>
                                 <tr>
                                    <td valign="top" align="left" scope="row" colspan="1" rowspan="1"> 2</td>
                                    <td valign="top" align="center" colspan="1" rowspan="1">8839 (6.3)</td>
                                    <td valign="top" align="center" colspan="1" rowspan="1">171 (2.4)</td>
                                    <td valign="top" align="center" colspan="1" rowspan="1">8668 (6.5)</td>
                                 </tr>
                                 <tr>
                                    <td valign="top" align="left" scope="row" colspan="1" rowspan="1"> 3</td>
                                    <td valign="top" align="center" colspan="1" rowspan="1">10 003 (7.1)</td>
                                    <td valign="top" align="center" colspan="1" rowspan="1">254 (3.5)</td>
                                    <td valign="top" align="center" colspan="1" rowspan="1">9749 (7.3)</td>
                                 </tr>
                                 <tr>
                                    <td valign="top" align="left" scope="row" colspan="1" rowspan="1"> ≥4</td>
                                    <td valign="top" align="center" colspan="1" rowspan="1">108 894 (77.1)</td>
                                    <td valign="top" align="center" colspan="1" rowspan="1">6644 (91.9)</td>
                                    <td valign="top" align="center" colspan="1" rowspan="1">102 250 (76.3)</td>
                                 </tr>
                              </tbody>
                           </table>
                        </div>
                        <div class="table-wrap-foot">
                           <p class="p">DPP-4=dipeptidyl peptidase-4.</p><span class="fn" id="t1n1"><span class="label">*</span><p class="p">Non-mutually exclusive groups measured at any time before (not including) cohort entry.</p></span></div>
                     </div>
                  </div>
               </div>
               <p class="p"><a class="xref" ref-type="table" href="#tbl2">Table 2</a> shows the results of the primary and secondary analyses. Compared with use of other
                  antidiabetic drugs, use of dipeptidyl peptidase-4 inhibitors was associated with a
                  75% increase in risk of inflammatory bowel disease (53.4 <i class="italic">v</i> 34.5 per 100 000 per year; hazard ratio 1.75, 95% confidence interval 1.22 to 2.49).
                  The number needed to harm corresponded to 2291 patients followed over a two year period
                  and 1177 over a four year period. In secondary analyses, hazard ratios gradually increased
                  with longer durations of use, reaching a peak after three to four years of use (hazard
                  ratio 2.90, 1.31 to 6.41) and decreasing after more than four years of use (1.45,
                  0.44 to 4.76). A similar pattern was observed with time since initiation, with the
                  highest hazard ratio observed between two and four years after initiation (2.50, 1.57
                  to 3.99) and a decrease after more than four years (1.75, 0.86 to 3.58). These patterns
                  remained consistent in the cubic spine models (supplementary figures A and B).
               </p>
               <div class="clickForTable"><b><a id="tbl2" href="#openModal2">Table&nbsp;2</a></b><div id="openModal2" class="modalDialog">
                     <div><span class="label">Table 2</span><div class="caption">
                           <p class="p">Crude and adjusted hazard ratios for association between use of DPP-4 inhibitors and
                              risk of inflammatory bowel disease
                           </p>
                        </div>
                        <div class="modalWindow"><a href="#close" title="Close" class="close">X</a><table class="modalTable" frame="above" rules="groups">
                              <col width="32.63%">
                              <col width="8.33%">
                              <col width="11.46%">
                              <col width="20.83%">
                              <col width="9.77%">
                              <col width="16.98%">
                              <thead>
                                 <tr>
                                    <th rowspan="2" valign="bottom" align="left" scope="col" colspan="1">Exposure</th>
                                    <th rowspan="2" valign="bottom" align="center" scope="col" colspan="1">Events</th>
                                    <th rowspan="2" valign="bottom" align="center" scope="col" colspan="1">Person years</th>
                                    <th rowspan="2" valign="bottom" align="center" scope="col" colspan="1">Incidence rate (95% CI)<a class="xref" ref-type="table-fn" href="#t2n1">*</a></th>
                                    <th valign="bottom" colspan="2" align="center" scope="colgroup" rowspan="1">Hazard ratio (95% CI)</th>
                                 </tr>
                                 <tr>
                                    <th valign="bottom" colspan="1" align="center" scope="colgroup" rowspan="1">Crude</th>
                                    <th valign="bottom" align="center" scope="col" colspan="1" rowspan="1">Adjusted<a class="xref" ref-type="table-fn" href="#t2n2">†</a></th>
                                 </tr>
                              </thead>
                              <tbody>
                                 <tr>
                                    <td valign="middle" align="left" scope="row" colspan="1" rowspan="1">Use of other antidiabetic drugs</td>
                                    <td valign="middle" align="center" colspan="1" rowspan="1">159</td>
                                    <td valign="middle" align="center" colspan="1" rowspan="1">460 623</td>
                                    <td valign="middle" align="center" colspan="1" rowspan="1">34.5 (29.4 to 40.3)</td>
                                    <td valign="middle" align="center" colspan="1" rowspan="1">1.00</td>
                                    <td valign="middle" align="center" colspan="1" rowspan="1">1.00 (reference)</td>
                                 </tr>
                                 <tr>
                                    <td valign="middle" align="left" scope="row" colspan="1" rowspan="1">DPP-4 inhibitors</td>
                                    <td valign="middle" align="center" colspan="1" rowspan="1">49</td>
                                    <td valign="middle" align="center" colspan="1" rowspan="1">91 790</td>
                                    <td valign="middle" align="center" colspan="1" rowspan="1">53.4 (39.5 to 70.6)</td>
                                    <td valign="middle" align="center" colspan="1" rowspan="1">1.59</td>
                                    <td valign="middle" align="center" colspan="1" rowspan="1">1.75 (1.22 to 2.49)</td>
                                 </tr>
                                 <tr>
                                    <td valign="middle" align="left" scope="col" colspan="1" rowspan="1">Cumulative duration of DPP-4 inhibitor use, years:</td>
                                    <td valign="middle" align="left" colspan="1" rowspan="1"></td>
                                    <td valign="middle" align="left" colspan="1" rowspan="1"></td>
                                    <td valign="middle" align="left" colspan="1" rowspan="1"></td>
                                    <td valign="middle" align="left" colspan="1" rowspan="1"></td>
                                    <td valign="middle" align="left" colspan="1" rowspan="1"></td>
                                 </tr>
                                 <tr>
                                    <td valign="middle" align="left" scope="row" colspan="1" rowspan="1"> ≤1</td>
                                    <td valign="middle" align="center" colspan="1" rowspan="1">16</td>
                                    <td valign="middle" align="center" colspan="1" rowspan="1">36 030</td>
                                    <td valign="middle" align="center" colspan="1" rowspan="1">44.4 (25.4 to 72.1)</td>
                                    <td valign="middle" align="center" colspan="1" rowspan="1">1.32</td>
                                    <td valign="middle" align="center" colspan="1" rowspan="1">1.42 (0.84 to 2.41)</td>
                                 </tr>
                                 <tr>
                                    <td valign="middle" align="left" scope="row" colspan="1" rowspan="1"> 1.1-2</td>
                                    <td valign="middle" align="center" colspan="1" rowspan="1">15</td>
                                    <td valign="middle" align="center" colspan="1" rowspan="1">25 491</td>
                                    <td valign="middle" align="center" colspan="1" rowspan="1">58.8 (32.9 to 97.1)</td>
                                    <td valign="middle" align="center" colspan="1" rowspan="1">1.70</td>
                                    <td valign="middle" align="center" colspan="1" rowspan="1">1.91 (1.11 to 3.32)</td>
                                 </tr>
                                 <tr>
                                    <td valign="middle" align="left" scope="row" colspan="1" rowspan="1"> 2.1-3</td>
                                    <td valign="middle" align="center" colspan="1" rowspan="1">S<a class="xref" ref-type="table-fn" href="#t2n3">‡</a></td>
                                    <td valign="middle" align="center" colspan="1" rowspan="1">S<a class="xref" ref-type="table-fn" href="#t2n3">‡</a></td>
                                    <td valign="middle" align="center" colspan="1" rowspan="1">55.8 (24.1 to 110.0)</td>
                                    <td valign="middle" align="center" colspan="1" rowspan="1">1.69</td>
                                    <td valign="middle" align="center" colspan="1" rowspan="1">1.90 (0.91 to 3.96)</td>
                                 </tr>
                                 <tr>
                                    <td valign="middle" align="left" scope="row" colspan="1" rowspan="1"> 3.1-4</td>
                                    <td valign="middle" align="center" colspan="1" rowspan="1">7</td>
                                    <td valign="middle" align="center" colspan="1" rowspan="1">8423</td>
                                    <td valign="middle" align="center" colspan="1" rowspan="1">83.1 (33.4 to 171.2)</td>
                                    <td valign="middle" align="center" colspan="1" rowspan="1">2.56</td>
                                    <td valign="middle" align="center" colspan="1" rowspan="1">2.90 (1.31 to 6.41)</td>
                                 </tr>
                                 <tr>
                                    <td valign="middle" align="left" scope="row" colspan="1" rowspan="1"> &gt;4</td>
                                    <td valign="middle" align="center" colspan="1" rowspan="1">S<a class="xref" ref-type="table-fn" href="#t2n3">‡</a></td>
                                    <td valign="middle" align="center" colspan="1" rowspan="1">S<a class="xref" ref-type="table-fn" href="#t2n3">‡</a></td>
                                    <td valign="middle" align="center" colspan="1" rowspan="1">39.9 (8.2 to 116.7)</td>
                                    <td valign="middle" align="center" colspan="1" rowspan="1">1.28</td>
                                    <td valign="middle" align="center" colspan="1" rowspan="1">1.45 (0.44 to 4.76)</td>
                                 </tr>
                                 <tr>
                                    <td valign="middle" align="left" scope="col" colspan="1" rowspan="1">Time since first DPP-4 inhibitor prescription, years:</td>
                                    <td valign="middle" align="left" colspan="1" rowspan="1"></td>
                                    <td valign="middle" align="left" colspan="1" rowspan="1"></td>
                                    <td valign="middle" align="left" colspan="1" rowspan="1"></td>
                                    <td valign="middle" align="left" colspan="1" rowspan="1"></td>
                                    <td valign="middle" align="left" colspan="1" rowspan="1"></td>
                                 </tr>
                                 <tr>
                                    <td valign="middle" align="left" scope="row" colspan="1" rowspan="1"> ≤2</td>
                                    <td valign="middle" align="center" colspan="1" rowspan="1">15</td>
                                    <td valign="middle" align="center" colspan="1" rowspan="1">38 608</td>
                                    <td valign="middle" align="center" colspan="1" rowspan="1">38.9 (21.7 to 64.1)</td>
                                    <td valign="middle" align="center" colspan="1" rowspan="1">1.12</td>
                                    <td valign="middle" align="center" colspan="1" rowspan="1">1.23 (0.72 to 2.11)</td>
                                 </tr>
                                 <tr>
                                    <td valign="middle" align="left" scope="row" colspan="1" rowspan="1"> 2.1-4</td>
                                    <td valign="middle" align="center" colspan="1" rowspan="1">24</td>
                                    <td valign="middle" align="center" colspan="1" rowspan="1">32 385</td>
                                    <td valign="middle" align="center" colspan="1" rowspan="1">74.1 (47.5 to 110.3)</td>
                                    <td valign="middle" align="center" colspan="1" rowspan="1">2.24</td>
                                    <td valign="middle" align="center" colspan="1" rowspan="1">2.50 (1.57 to 3.99)</td>
                                 </tr>
                                 <tr>
                                    <td valign="middle" align="left" scope="row" colspan="1" rowspan="1"> &gt;4</td>
                                    <td valign="middle" align="center" colspan="1" rowspan="1">10</td>
                                    <td valign="middle" align="center" colspan="1" rowspan="1">20 797</td>
                                    <td valign="middle" align="center" colspan="1" rowspan="1">48.1 (23.1 to 88.4)</td>
                                    <td valign="middle" align="center" colspan="1" rowspan="1">1.56</td>
                                    <td valign="middle" align="center" colspan="1" rowspan="1">1.75 (0.86 to 3.58)</td>
                                 </tr>
                              </tbody>
                           </table>
                        </div>
                        <div class="table-wrap-foot">
                           <p class="p">DPP-4=dipeptidyl peptidase-4.</p><span class="fn" id="t2n1"><span class="label">*</span><p class="p">Per 100 000 person years.</p></span><span class="fn" id="t2n2"><span class="label"><sup class="sup">†</sup></span><p class="p">Adjusted for age, sex, year of cohort entry, body mass index, alcohol related disorders
                                 (including alcoholism, alcoholic cirrhosis of liver, alcoholic hepatitis, and hepatic
                                 failure), smoking status, haemoglobin A<sub class="sub">1c</sub>, microvascular (nephropathy, neuropathy, retinopathy) and macrovascular (myocardial
                                 infarction, stroke, peripheral arteriopathy) complications of diabetes, duration of
                                 treated diabetes, antidiabetic drugs used before cohort entry, use of aspirin, non-steroidal
                                 anti-inflammatory drugs, hormonal replacement therapy, oral contraceptives, other
                                 autoimmune conditions, total number of unique non-diabetic drugs in year before cohort
                                 entry.
                              </p></span><span class="fn" id="t2n3"><span class="label">‡</span><p class="p">Numbers &lt;5 are not shown, as per confidentiality policies of Clinical Practice Research
                                 Datalink.
                              </p></span></div>
                     </div>
                  </div>
               </div>
               <p class="p">Overall, no single dipeptidyl peptidase-4 inhibitor drug was statistically associated
                  with inflammatory bowel disease, although the strata had few events (supplementary
                  table C). In analyses stratified on type of inflammatory bowel disease, the use of
                  dipeptidyl peptidase-4 inhibitors was associated with a greater than twofold increase
                  in risk of ulcerative colitis (hazard ratio 2.23, 1.32 to 3.76), whereas no statistically
                  significant association was observed with Crohn’s disease (0.87, 0.37 to 2.09) (supplementary
                  table D).
               </p>
               <div class="sec">
                  <div class="title" id="Sensitivity and ancillary analyses">Sensitivity and ancillary analyses</div>
                  <p class="p"><a class="xref" ref-type="fig" href="#f2">Figure 2</a> summarises the results of the sensitivity analyses (shown in detail in supplementary
                     tables E-N and supplementary figure C). Overall, these analyses produced results that
                     were consistent with those of the primary analysis, with statistically significant
                     hazard ratios ranging between 1.60 and 2.21. The negative control analysis comparing
                     the use of insulin with the use of other antidiabetic drugs yielded a hazard ratio
                     close to the null value (0.92, 0.53 to 1.58; <a class="xref" ref-type="table" href="#tbl3">table 3</a>). In the head to head comparison, use of dipeptidyl peptidase-4 inhibitors was associated
                     with a greater than twofold increase in risk of inflammatory bowel disease, compared
                     with insulin (hazard ratio 2.28, 1.07 to 4.85) (<a class="xref" ref-type="table" href="#tbl3">table 3</a>, supplementary figure D and supplementary table O).
                  </p>
                  <div id="f2" class="fig f2 float figure"><span class="label">Fig 2</span><div class="caption">
                        <p class="p">Forest plot summarising results of primary analysis and sensitivity analyses, showing
                           adjusted hazard ratios and 95% CIs for association between use of dipeptidyl peptidase-4
                           inhibitors and inflammatory bowel disease
                        </p>
                     </div><img src="graphics\abrd041828.f2.jpg"></div>
                  <div class="clickForTable"><b><a id="tbl3" href="#openModal3">Table&nbsp;3</a></b><div id="openModal3" class="modalDialog">
                        <div><span class="label">Table 3</span><div class="caption">
                              <p class="p">Ancillary analyses of insulin as negative control exposure and head to head comparison
                                 of DPP-4 inhibitors versus insulin on risk of inflammatory bowel disease
                              </p>
                           </div>
                           <div class="modalWindow"><a href="#close" title="Close" class="close">X</a><table class="modalTable" frame="above" rules="groups">
                                 <col width="27.73%">
                                 <col width="11.34%">
                                 <col width="15.91%">
                                 <col width="23.56%">
                                 <col width="21.46%">
                                 <thead>
                                    <tr>
                                       <th valign="bottom" align="left" scope="col" colspan="1" rowspan="1">Analysis</th>
                                       <th valign="bottom" align="center" scope="col" colspan="1" rowspan="1">Events</th>
                                       <th valign="bottom" align="center" scope="col" colspan="1" rowspan="1">Person years</th>
                                       <th valign="bottom" align="center" scope="col" colspan="1" rowspan="1">Incidence rate (95% CI)<a class="xref" ref-type="table-fn" href="#t3n1">*</a></th>
                                       <th valign="bottom" align="center" scope="col" colspan="1" rowspan="1">Adjusted hazard ratio (95% CI)<a class="xref" ref-type="table-fn" href="#t3n2">†</a><a class="xref" ref-type="table-fn" href="#t3n3">‡</a></th>
                                    </tr>
                                 </thead>
                                 <tbody>
                                    <tr>
                                       <td valign="middle" align="left" scope="col" colspan="1" rowspan="1"><b class="bold">Insulin negative control exposure</b></td>
                                       <td valign="middle" align="left" colspan="1" rowspan="1"></td>
                                       <td valign="middle" align="left" colspan="1" rowspan="1"></td>
                                       <td valign="middle" align="left" colspan="1" rowspan="1"></td>
                                       <td valign="middle" align="left" colspan="1" rowspan="1"></td>
                                    </tr>
                                    <tr>
                                       <td valign="middle" align="left" scope="row" colspan="1" rowspan="1">No use of insulin</td>
                                       <td valign="middle" align="center" colspan="1" rowspan="1">188</td>
                                       <td valign="middle" align="center" colspan="1" rowspan="1">502 896</td>
                                       <td valign="middle" align="center" colspan="1" rowspan="1">37.4 (32.2 to 43.1)</td>
                                       <td valign="middle" align="center" colspan="1" rowspan="1">1.00 (reference)</td>
                                    </tr>
                                    <tr>
                                       <td valign="middle" align="left" scope="row" colspan="1" rowspan="1">Insulin</td>
                                       <td valign="middle" align="center" colspan="1" rowspan="1">18</td>
                                       <td valign="middle" align="center" colspan="1" rowspan="1">44 800</td>
                                       <td valign="middle" align="center" colspan="1" rowspan="1">40.2 (23.8 to 63.5)</td>
                                       <td valign="middle" align="center" colspan="1" rowspan="1">0.92 (0.53 to 1.58)</td>
                                    </tr>
                                    <tr>
                                       <td valign="middle" align="left" scope="col" colspan="1" rowspan="1"><b class="bold">Head to head comparison</b></td>
                                       <td valign="middle" align="left" colspan="1" rowspan="1"></td>
                                       <td valign="middle" align="left" colspan="1" rowspan="1"></td>
                                       <td valign="middle" align="left" colspan="1" rowspan="1"></td>
                                       <td valign="middle" align="left" colspan="1" rowspan="1"></td>
                                    </tr>
                                    <tr>
                                       <td valign="middle" align="left" scope="row" colspan="1" rowspan="1">Insulin</td>
                                       <td valign="middle" align="center" colspan="1" rowspan="1">11</td>
                                       <td valign="middle" align="center" colspan="1" rowspan="1">31 870</td>
                                       <td valign="middle" align="center" colspan="1" rowspan="1">34.5 (17.2 to 61.8)</td>
                                       <td valign="middle" align="center" colspan="1" rowspan="1">1.00 (reference)</td>
                                    </tr>
                                    <tr>
                                       <td valign="middle" align="left" scope="row" colspan="1" rowspan="1">DPP-4 inhibitors</td>
                                       <td valign="middle" align="center" colspan="1" rowspan="1">40</td>
                                       <td valign="middle" align="center" colspan="1" rowspan="1">77 476</td>
                                       <td valign="middle" align="center" colspan="1" rowspan="1">51.6 (36.9 to 70.3)</td>
                                       <td valign="middle" align="center" colspan="1" rowspan="1">2.28 (1.07 to 4.85)</td>
                                    </tr>
                                 </tbody>
                              </table>
                           </div>
                           <div class="table-wrap-foot">
                              <p class="p">DPP-4=dipeptidyl peptidase-4.</p><span class="fn" id="t3n1"><span class="label">*</span><p class="p">Per 100 000 person years.</p></span><span class="fn" id="t3n2"><span class="label">†</span><p class="p">Insulin negative control: adjusted for age, sex, year of cohort entry, body mass index,
                                    alcohol related disorders (including alcoholism, alcoholic cirrhosis of liver, alcoholic
                                    hepatitis, and hepatic failure), smoking status, haemoglobin A<sub class="sub">1c</sub>, microvascular (nephropathy, neuropathy, retinopathy) and macrovascular (myocardial
                                    infarction, stroke, peripheral arteriopathy) complications of diabetes, duration of
                                    treated diabetes, antidiabetic drugs used before cohort entry, use of aspirin, non-steroidal
                                    anti-inflammatory drugs, hormonal replacement therapy, oral contraceptives, other
                                    autoimmune conditions, total number of unique non-diabetic drugs in year before cohort
                                    entry.
                                 </p></span><span class="fn" id="t3n3"><span class="label">‡</span><p class="p">Head to head comparison: stratified on fifths of propensity score.</p></span></div>
                        </div>
                     </div>
                  </div>
               </div>
            </div>
            <div class="sec discussion">
               <div class="title" id="Discussion">Discussion</div>
               <p class="p">To our knowledge, this is the first observational study to specifically investigate
                  the association between the use of dipeptidyl peptidase-4 inhibitors and the incidence
                  of inflammatory bowel disease. Use of dipeptidyl peptidase-4 inhibitors was associated
                  with an overall 75% increase in risk of inflammatory bowel disease. In secondary analyses,
                  the association was particularly elevated between three and four years of use and
                  between two and four years after the start of dipeptidyl peptidase-4 inhibitor treatment.
                  This gradual increase in the risk is consistent with the hypothesis of a possible
                  delayed effect of the use of dipeptidyl peptidase-4 inhibitors on the incidence of
                  inflammatory bowel disease. This association remained highly consistent across a variety
                  of sensitivity analyses.
               </p>
               <div class="sec">
                  <div class="title" id="Comparison with previous studies">Comparison with previous studies</div>
                  <p class="p">The dipeptidyl peptidase-4 enzyme is involved in inflammatory response and is known
                     to modulate gastric hormones; these have been shown to be elevated in patients with
                     inflammatory bowel disease.<a class="xref" ref-type="bibr" href="#ref31">31</a> However, further study of the exact effect of this enzyme in inflammatory bowel disease
                     is needed. Inhibition of this enzyme with dipeptidyl peptidase-4 inhibitors has been
                     shown to reduce disease activity in Crohn’s disease by increasing concentrations of
                     glucagon-like peptide 2, an incretin hormone with intestinotrophic effects.<a class="xref" ref-type="bibr" href="#ref7">7</a> Furthermore, in experimental mouse models of colitis, treatment with dipeptidyl peptidase-4
                     inhibitors decreased both disease activity and disease severity, through inhibition
                     of T cell proliferation and cytokine production and restoration of gut mucosal damage,
                     respectively.<a class="xref" ref-type="bibr" href="#ref8">8</a><a class="xref" ref-type="bibr" href="#ref9">9</a><a class="xref" ref-type="bibr" href="#ref10">10</a> However, the available clinical evidence shows a complex relation between the dipeptidyl
                     peptidase-4 enzyme and inflammatory bowel disease activity. Although the expression
                     of dipeptidyl peptidase-4 was elevated on T cells from patients with inflammatory
                     bowel disease,<a class="xref" ref-type="bibr" href="#ref6">6</a><a class="xref" ref-type="bibr" href="#ref7">7</a> serum concentrations and activity of dipeptidyl peptidase-4 were lower compared with
                     healthy controls.<a class="xref" ref-type="bibr" href="#ref6">6</a><a class="xref" ref-type="bibr" href="#ref11">11</a><a class="xref" ref-type="bibr" href="#ref12">12</a> Moreover, dipeptidyl peptidase-4 enzyme concentrations had an inverse relation with
                     inflammatory bowel disease activity scores, although the direction of this association
                     remains unclear.<a class="xref" ref-type="bibr" href="#ref12">12</a><a class="xref" ref-type="bibr" href="#ref13">13</a></p>
                  <p class="p">In contrast to the aforementioned animal studies that have supported a role for dipeptidyl
                     peptidase-4 inhibitors in the treatment of inflammatory bowel disease,<a class="xref" ref-type="bibr" href="#ref7">7</a><a class="xref" ref-type="bibr" href="#ref8">8</a><a class="xref" ref-type="bibr" href="#ref9">9</a><a class="xref" ref-type="bibr" href="#ref10">10</a> our study focused on incident inflammatory bowel disease, in which dipeptidyl peptidase-4
                     may have a different biological function. Although one previous observational study
                     reported a decreased risk of a composite of several autoimmune diseases (including
                     inflammatory bowel disease) with the use of dipeptidyl peptidase-4 inhibitors (hazard
                     ratio 0.68, 95% confidence interval 0.52 to 0.89),<a class="xref" ref-type="bibr" href="#ref28">28</a> it did not report any findings on inflammatory bowel disease specifically. This decreased
                     risk may have been driven by other diseases included in the composite outcome. Finally,
                     our results indicate that an increased risk with dipeptidyl peptidase-4 inhibitors
                     may be associated with ulcerative colitis and not Crohn’s disease. However, this finding
                     should be interpreted with caution as this stratified analysis was based on few events,
                     generating a wide confidence interval with an upper 95% confidence limit of 2.09.
                     Thus, our results do not rule out a possible association with Crohn’s disease as well.
                     In summary, although our findings need to be replicated, additional studies are also
                     needed to understand the possible mechanism through which dipeptidyl peptidase-4 inhibitors
                     may increase the risk of inflammatory bowel disease.
                  </p>
               </div>
               <div class="sec">
                  <div class="title" id="Strengths and limitations of study">Strengths and limitations of study</div>
                  <p class="p">This study has several strengths. Firstly, our study design excluded prevalent users,
                     thus eliminating biases associated with their inclusion.<a class="xref" ref-type="bibr" href="#ref32">32</a> Secondly, we used a time dependent exposure definition that allowed patients to contribute
                     both unexposed and exposed person time, thereby eliminating immortal time bias.<a class="xref" ref-type="bibr" href="#ref33">33</a> Type 2 diabetes and inflammatory bowel disease have been shown to share inflammatory
                     pathways,<a class="xref" ref-type="bibr" href="#ref34">34</a> although large population based studies have not reported an association between
                     these two diseases.<a class="xref" ref-type="bibr" href="#ref35">35</a> Nevertheless, we rigorously assessed the effect of possible residual confounding
                     in several analyses; these analyses yielded consistent findings. Moreover, the null
                     association observed with insulin (a last line treatment of which the users are typically
                     at an advanced disease stage) as a negative control provides reassurance on the internal
                     validity of our findings. Finally, our results remained highly consistent across a
                     variety of sensitivity analyses intended to overcome different sources of bias.
                  </p>
                  <p class="p">Our study has a few limitations. As prescriptions in the CPRD are written by general
                     practitioners and not specialists, some exposure misclassification is possible. In
                     the UK, however, type 2 diabetes is managed almost entirely through primary care,<a class="xref" ref-type="bibr" href="#ref36">36</a> so such misclassification is likely to have been minimal. Although inflammatory bowel
                     disease has been shown to be well recorded in the CPRD,<a class="xref" ref-type="bibr" href="#ref18">18</a><a class="xref" ref-type="bibr" href="#ref19">19</a><a class="xref" ref-type="bibr" href="#ref20">20</a> outcome misclassification is also possible. Reassuringly, we observed consistent
                     findings in a sensitivity analysis using an algorithm based on clinically supporting
                     events. Finally, as with all observational studies, residual confounding from unknown
                     or unmeasured variables remains possible. However, on the basis of the rule out method,<a class="xref" ref-type="bibr" href="#ref29">29</a> a hypothetical confounder would need to be strongly associated with both the exposure
                     (odds ratio &gt;4.7) and the outcome (relative risk &gt;5.0) to move the point estimate
                     towards the null (supplementary figure C). Whether such a hypothetical confounder
                     exists beyond those considered in the analyses is unclear.
                  </p>
               </div>
               <div class="sec">
                  <div class="title" id="Conclusions">Conclusions</div>
                  <p class="p">The results of this large population based cohort study indicate that the use of dipeptidyl
                     peptidase-4 inhibitors is associated with an overall 75% increase in the risk of inflammatory
                     bowel disease in patients with type 2 diabetes. Although the absolute risk is low,
                     physicians should be aware of this possible association and perhaps refrain from prescribing
                     dipeptidyl peptidase-4 inhibitors for people at high risk (that is, those with a family
                     history of disease or with known autoimmune conditions). Moreover, patients presenting
                     with persistent gastrointestinal symptoms such as abdominal pain or diarrhoea should
                     be closely monitored for worsening of symptoms.
                  </p>
                  <div id="boxa" class="boxed-text boxa 4">
                     <div class="sec">
                        <div class="title" id="What is already known on this topic">What is already known on this topic</div>
                        <ul id="L1" list-type="simple">
                           <li>
                              <p class="p">The effect of the dipeptidyl peptidase-4 (DPP-4) enzyme in autoimmune diseases such
                                 as inflammatory bowel disease (IBD) is not well understood
                              </p>
                           </li>
                           <li>
                              <p class="p">Low concentrations of the DPP-4 enzyme have been associated with increased IBD activity,
                                 although the direction of this association remains unclear
                              </p>
                           </li>
                           <li>
                              <p class="p">No observational studies have investigated the association between the use of DPP-4
                                 inhibitors and the incidence of IBD
                              </p>
                           </li>
                        </ul>
                     </div>
                     <div class="sec">
                        <div class="title" id="What this study adds">What this study adds</div>
                        <ul id="L2" list-type="simple">
                           <li>
                              <p class="p">Use of DPP-4 inhibitors was associated with an overall 75% increase in the risk of
                                 IBD
                              </p>
                           </li>
                           <li>
                              <p class="p">This association was elevated between three and four years of use and between two
                                 and four years after the start of treatment
                              </p>
                           </li>
                           <li>
                              <p class="p">These findings need to be replicated, but physicians should be made aware of this
                                 possible association
                              </p>
                           </li>
                        </ul>
                     </div>
                  </div>
               </div>
            </div>
         </div>
         <div class="back">
            <h2>Notes</h2><span class="label">Web Extra</span><p class="p">Extra material supplied by the author</p>
            <div><a href="data-supp">
                  <div class="caption">
                     <p class="p">Supplementary materials</p>
                  </div>
                  <div class="media abrd041828.ww1"></div></a></div>
            <h2>Notes</h2><span class="fn" fn-type="participating-researchers">
               <p class="p">Contributors: All authors conceived and designed the study. LA acquired the data.
                  DA, AD, HY, and LA did the statistical analyses. All authors analysed and interpreted
                  the data. DA wrote the manuscript, and all authors critically revised it. All authors
                  approved the final version of the manuscript and agree to be accountable for the accuracy
                  of the work. LA supervised the study and is the guarantor.
               </p></span><span class="fn" fn-type="financial-disclosure">
               <p class="p">Funding: This study was funded by a foundation scheme grant from the Canadian Institutes
                  of Health Research. The sponsor had no influence on design and conduct of the study;
                  collection, management, analysis, and interpretation of the data; and preparation,
                  review, or approval of the manuscript. AD is the recipient of a research fellowship
                  from the German Research Foundation (Deutsche Forschungsgemeinschaft, DFG). LA holds
                  a Chercheur-Boursier junior 2 award from the Fonds de Recherche du Québec - Santé
                  and is the recipient of a William Dawson scholar award from McGill University.
               </p></span><span class="fn" fn-type="conflict">
               <p class="p">Competing interests: All authors have completed the ICMJE uniform disclosure form
                  at <a href="http://www.icmje.org/coi_disclosure.pdf">www.icmje.org/coi_disclosure.pdf</a> (available on request from the corresponding author) and declare: this study was
                  funded by the Canadian Institutes of Health Research; no financial relationships with
                  any organisations that might have an interest in the submitted work in the previous
                  three years; no other relationships or activities that could appear to have influenced
                  the submitted work.
               </p></span><span class="fn" fn-type="other">
               <p class="p">Ethical approval: The study protocol was approved by the Independent Scientific Advisory
                  Committee of the Clinical Practice Research Datalink (protocol number 17_165R) and
                  by the Research Ethics Board of Jewish General Hospital, Montreal, Quebec, Canada.
               </p></span><span class="fn" fn-type="other">
               <p class="p">Data sharing: No additional data available.</p></span><span class="fn" fn-type="other">
               <p class="p">Transparency: The guarantor (LA) affirms that this manuscript is an honest, accurate,
                  and transparent account of the study being reported; that no important aspects of
                  the study have been omitted; and that any discrepancies from the study as planned
                  (and, if relevant, registered) have been explained.
               </p></span><h2>References</h2>
            <div class="ref-list">
               <div id="ref1" class="ref ref1"><span class="label">1</span><span class="mixed-citation journal"><span class="person-group author"><span class="name"><span class="surname">Christensen</span><span class="given-names">DH</span></span><span class="name"><span class="surname">Rungby</span><span class="given-names">J</span></span><span class="name"><span class="surname">Thomsen</span><span class="given-names">RW</span></span></span>. <span class="ref-article-title">Nationwide trends in glucose-lowering drug use, Denmark, 1999-2014</span>. <span class="source">Clin Epidemiol</span><span class="year">2016</span>;<span class="volume">8</span>:381-<span class="lpage">7</span>. &nbsp;<a href="http://dx.doi.org/10.2147/CLEP.S113211">10.2147/CLEP.S113211</a>&nbsp;&nbsp;&nbsp;<a href="http://www.ncbi.nlm.nih.gov/pubmed/?term=27789974">pmid:27789974</a></span></div>
               <div id="ref2" class="ref ref2"><span class="label">2</span><span class="mixed-citation journal"><span class="person-group author"><span class="name"><span class="surname">Thornberry</span><span class="given-names">NA</span></span><span class="name"><span class="surname">Gallwitz</span><span class="given-names">B</span></span></span>. <span class="ref-article-title">Mechanism of action of inhibitors of dipeptidyl-peptidase-4 (DPP-4)</span>. <span class="source">Best Pract Res Clin Endocrinol Metab</span><span class="year">2009</span>;<span class="volume">23</span>:479-<span class="lpage">86</span>. &nbsp;<a href="http://dx.doi.org/10.1016/j.beem.2009.03.004">10.1016/j.beem.2009.03.004</a>&nbsp;&nbsp;&nbsp;<a href="http://www.ncbi.nlm.nih.gov/pubmed/?term=19748065">pmid:19748065</a></span></div>
               <div id="ref3" class="ref ref3"><span class="label">3</span><span class="mixed-citation journal"><span class="person-group author"><span class="name"><span class="surname">Nauck</span><span class="given-names">MA</span></span><span class="name"><span class="surname">Vilsbøll</span><span class="given-names">T</span></span><span class="name"><span class="surname">Gallwitz</span><span class="given-names">B</span></span><span class="name"><span class="surname">Garber</span><span class="given-names">A</span></span><span class="name"><span class="surname">Madsbad</span><span class="given-names">S</span></span></span>. <span class="ref-article-title">Incretin-based therapies: viewpoints on the way to consensus</span>. <span class="source">Diabetes Care</span><span class="year">2009</span>;<span class="volume">32</span>(<span class="supplement">Suppl 2</span>):S223-<span class="lpage">31</span>. &nbsp;<a href="http://dx.doi.org/10.2337/dc09-S315">10.2337/dc09-S315</a>&nbsp;&nbsp;&nbsp;<a href="http://www.ncbi.nlm.nih.gov/pubmed/?term=19875556">pmid:19875556</a></span></div>
               <div id="ref4" class="ref ref4"><span class="label">4</span><span class="mixed-citation journal"><span class="person-group author"><span class="name"><span class="surname">Son</span><span class="given-names">JW</span></span><span class="name"><span class="surname">Kim</span><span class="given-names">S</span></span></span>. <span class="ref-article-title">Dipeptidyl Peptidase 4 Inhibitors and the Risk of Cardiovascular Disease in Patients
                        with Type 2 Diabetes: A Tale of Three Studies</span>. <span class="source">Diabetes Metab J</span><span class="year">2015</span>;<span class="volume">39</span>:373-<span class="lpage">83</span>. &nbsp;<a href="http://dx.doi.org/10.4093/dmj.2015.39.5.373">10.4093/dmj.2015.39.5.373</a>&nbsp;&nbsp;&nbsp;<a href="http://www.ncbi.nlm.nih.gov/pubmed/?term=26566494">pmid:26566494</a></span></div>
               <div id="ref5" class="ref ref5"><span class="label">5</span><span class="mixed-citation book"><span class="person-group author"><span class="name"><span class="surname">Chen</span><span class="given-names">X</span></span></span>. <span class="chapter-title">Biochemical Properties of Recombinant Prolyl Dipeptidases DPP-IV and DPP8.</span> In: <span class="person-group editor"><span class="name"><span class="surname">Lendeckel</span><span class="given-names">U</span></span><span class="name"><span class="surname">Reinhold</span><span class="given-names">D</span></span><span class="name"><span class="surname">Bank</span><span class="given-names">U</span></span></span>, eds. <span class="source">Dipeptidyl Aminopeptidases: Basic Science and Clinical Applications.</span><span class="publisher-name">Springer US</span>,<span class="year"> 2006</span>: 27-<span class="lpage">32</span>&nbsp;<a href="http://dx.doi.org/10.1007/0-387-32824-6_3">10.1007/0-387-32824-6_3</a>.</span></div>
               <div id="ref6" class="ref ref6"><span class="label">6</span><span class="mixed-citation journal"><span class="person-group author"><span class="name"><span class="surname">Ohnuma</span><span class="given-names">K</span></span><span class="name"><span class="surname">Hosono</span><span class="given-names">O</span></span><span class="name"><span class="surname">Dang</span><span class="given-names">NH</span></span><span class="name"><span class="surname">Morimoto</span><span class="given-names">C</span></span></span>. <span class="ref-article-title">Dipeptidyl peptidase in autoimmune pathophysiology</span>. <span class="source">Adv Clin Chem</span><span class="year">2011</span>;<span class="volume">53</span>:51-<span class="lpage">84</span>. &nbsp;<a href="http://dx.doi.org/10.1016/B978-0-12-385855-9.00003-5">10.1016/B978-0-12-385855-9.00003-5</a>&nbsp;&nbsp;&nbsp;<a href="http://www.ncbi.nlm.nih.gov/pubmed/?term=21404914">pmid:21404914</a></span></div>
               <div id="ref7" class="ref ref7"><span class="label">7</span><span class="mixed-citation journal"><span class="person-group author"><span class="name"><span class="surname">Klemann</span><span class="given-names">C</span></span><span class="name"><span class="surname">Wagner</span><span class="given-names">L</span></span><span class="name"><span class="surname">Stephan</span><span class="given-names">M</span></span><span class="name"><span class="surname">von Hörsten</span><span class="given-names">S</span></span></span>. <span class="ref-article-title">Cut to the chase: a review of CD26/dipeptidyl peptidase-4's (DPP4) entanglement in
                        the immune system</span>. <span class="source">Clin Exp Immunol</span><span class="year">2016</span>;<span class="volume">185</span>:1-<span class="lpage">21</span>. &nbsp;<a href="http://dx.doi.org/10.1111/cei.12781">10.1111/cei.12781</a>&nbsp;&nbsp;&nbsp;<a href="http://www.ncbi.nlm.nih.gov/pubmed/?term=26919392">pmid:26919392</a></span></div>
               <div id="ref8" class="ref ref8"><span class="label">8</span><span class="mixed-citation journal"><span class="person-group author"><span class="name"><span class="surname">Yazbeck</span><span class="given-names">R</span></span><span class="name"><span class="surname">Howarth</span><span class="given-names">GS</span></span><span class="name"><span class="surname">Abbott</span><span class="given-names">CA</span></span></span>. <span class="ref-article-title">Dipeptidyl peptidase inhibitors, an emerging drug class for inflammatory disease?</span><span class="source">Trends Pharmacol Sci</span><span class="year">2009</span>;<span class="volume">30</span>:600-<span class="lpage">7</span>. &nbsp;<a href="http://dx.doi.org/10.1016/j.tips.2009.08.003">10.1016/j.tips.2009.08.003</a>&nbsp;&nbsp;&nbsp;<a href="http://www.ncbi.nlm.nih.gov/pubmed/?term=19837468">pmid:19837468</a></span></div>
               <div id="ref9" class="ref ref9"><span class="label">9</span><span class="mixed-citation journal"><span class="person-group author"><span class="name"><span class="surname">Yazbeck</span><span class="given-names">R</span></span><span class="name"><span class="surname">Howarth</span><span class="given-names">GS</span></span><span class="name"><span class="surname">Geier</span><span class="given-names">MS</span></span><span class="name"><span class="surname">Demuth</span><span class="given-names">HU</span></span><span class="name"><span class="surname">Abbott</span><span class="given-names">CA</span></span></span>. <span class="ref-article-title">Inhibiting dipeptidyl peptidase activity partially ameliorates colitis in mice</span>. <span class="source">Front Biosci</span><span class="year">2008</span>;<span class="volume">13</span>:6850-<span class="lpage">8</span>. &nbsp;<a href="http://dx.doi.org/10.2741/3193">10.2741/3193</a>&nbsp;&nbsp;&nbsp;<a href="http://www.ncbi.nlm.nih.gov/pubmed/?term=18508699">pmid:18508699</a></span></div>
               <div id="ref10" class="ref ref10"><span class="label">10</span><span class="mixed-citation journal"><span class="person-group author"><span class="name"><span class="surname">Mimura</span><span class="given-names">S</span></span><span class="name"><span class="surname">Ando</span><span class="given-names">T</span></span><span class="name"><span class="surname">Ishiguro</span><span class="given-names">K</span></span>&nbsp;et al</span>. <span class="ref-article-title">Dipeptidyl peptidase-4 inhibitor anagliptin facilitates restoration of dextran sulfate
                        sodium-induced colitis</span>. <span class="source">Scand J Gastroenterol</span><span class="year">2013</span>;<span class="volume">48</span>:1152-<span class="lpage">9</span>. &nbsp;<a href="http://dx.doi.org/10.3109/00365521.2013.832366">10.3109/00365521.2013.832366</a>&nbsp;&nbsp;&nbsp;<a href="http://www.ncbi.nlm.nih.gov/pubmed/?term=24047394">pmid:24047394</a></span></div>
               <div id="ref11" class="ref ref11"><span class="label">11</span><span class="mixed-citation journal"><span class="person-group author"><span class="name"><span class="surname">Magro</span><span class="given-names">DO</span></span><span class="name"><span class="surname">Kotze</span><span class="given-names">PG</span></span><span class="name"><span class="surname">Martinez</span><span class="given-names">CAR</span></span>&nbsp;et al</span>. <span class="ref-article-title">Changes in serum levels of lipopolysaccharides and CD26 in patients with Crohn’s disease</span>. <span class="source">Intest Res</span><span class="year">2017</span>;<span class="volume">15</span>:352-<span class="lpage">7</span>. &nbsp;<a href="http://dx.doi.org/10.5217/ir.2017.15.3.352">10.5217/ir.2017.15.3.352</a>&nbsp;&nbsp;&nbsp;<a href="http://www.ncbi.nlm.nih.gov/pubmed/?term=28670232">pmid:28670232</a></span></div>
               <div id="ref12" class="ref ref12"><span class="label">12</span><span class="mixed-citation journal"><span class="person-group author"><span class="name"><span class="surname">Moran</span><span class="given-names">GW</span></span><span class="name"><span class="surname">O’Neill</span><span class="given-names">C</span></span><span class="name"><span class="surname">Padfield</span><span class="given-names">P</span></span><span class="name"><span class="surname">McLaughlin</span><span class="given-names">JT</span></span></span>. <span class="ref-article-title">Dipeptidyl peptidase-4 expression is reduced in Crohn’s disease</span>. <span class="source">Regul Pept</span><span class="year">2012</span>;<span class="volume">177</span>:40-<span class="lpage">5</span>. &nbsp;<a href="http://dx.doi.org/10.1016/j.regpep.2012.04.006">10.1016/j.regpep.2012.04.006</a>&nbsp;&nbsp;&nbsp;<a href="http://www.ncbi.nlm.nih.gov/pubmed/?term=22561447">pmid:22561447</a></span></div>
               <div id="ref13" class="ref ref13"><span class="label">13</span><span class="mixed-citation journal"><span class="person-group author"><span class="name"><span class="surname">Hildebrandt</span><span class="given-names">M</span></span><span class="name"><span class="surname">Rose</span><span class="given-names">M</span></span><span class="name"><span class="surname">Rüter</span><span class="given-names">J</span></span><span class="name"><span class="surname">Salama</span><span class="given-names">A</span></span><span class="name"><span class="surname">Mönnikes</span><span class="given-names">H</span></span><span class="name"><span class="surname">Klapp</span><span class="given-names">BF</span></span></span>. <span class="ref-article-title">Dipeptidyl peptidase IV (DP IV, CD26) in patients with inflammatory bowel disease</span>. <span class="source">Scand J Gastroenterol</span><span class="year">2001</span>;<span class="volume">36</span>:1067-<span class="lpage">72</span>. &nbsp;<a href="http://dx.doi.org/10.1080/003655201750422675">10.1080/003655201750422675</a>&nbsp;&nbsp;&nbsp;<a href="http://www.ncbi.nlm.nih.gov/pubmed/?term=11589380">pmid:11589380</a></span></div>
               <div id="ref14" class="ref ref14"><span class="label">14</span><span class="mixed-citation journal"><span class="person-group author"><span class="name"><span class="surname">Herrett</span><span class="given-names">E</span></span><span class="name"><span class="surname">Thomas</span><span class="given-names">SL</span></span><span class="name"><span class="surname">Schoonen</span><span class="given-names">WM</span></span><span class="name"><span class="surname">Smeeth</span><span class="given-names">L</span></span><span class="name"><span class="surname">Hall</span><span class="given-names">AJ</span></span></span>. <span class="ref-article-title">Validation and validity of diagnoses in the General Practice Research Database: a
                        systematic review</span>. <span class="source">Br J Clin Pharmacol</span><span class="year">2010</span>;<span class="volume">69</span>:4-<span class="lpage">14</span>. &nbsp;<a href="http://dx.doi.org/10.1111/j.1365-2125.2009.03537.x">10.1111/j.1365-2125.2009.03537.x</a>&nbsp;&nbsp;&nbsp;<a href="http://www.ncbi.nlm.nih.gov/pubmed/?term=20078607">pmid:20078607</a></span></div>
               <div id="ref15" class="ref ref15"><span class="label">15</span><span class="mixed-citation journal"><span class="person-group author"><span class="name"><span class="surname">Jick</span><span class="given-names">SS</span></span><span class="name"><span class="surname">Kaye</span><span class="given-names">JA</span></span><span class="name"><span class="surname">Vasilakis-Scaramozza</span><span class="given-names">C</span></span>&nbsp;et al</span>. <span class="ref-article-title">Validity of the general practice research database</span>. <span class="source">Pharmacotherapy</span><span class="year">2003</span>;<span class="volume">23</span>:686-<span class="lpage">9</span>. &nbsp;<a href="http://dx.doi.org/10.1592/phco.23.5.686.32205">10.1592/phco.23.5.686.32205</a>&nbsp;&nbsp;&nbsp;<a href="http://www.ncbi.nlm.nih.gov/pubmed/?term=12741446">pmid:12741446</a></span></div>
               <div id="ref16" class="ref ref16"><span class="label">16</span><span class="mixed-citation journal"><span class="person-group author"><span class="name"><span class="surname">Lawrenson</span><span class="given-names">R</span></span><span class="name"><span class="surname">Williams</span><span class="given-names">T</span></span><span class="name"><span class="surname">Farmer</span><span class="given-names">R</span></span></span>. <span class="ref-article-title">Clinical information for research; the use of general practice databases</span>. <span class="source">J Public Health Med</span><span class="year">1999</span>;<span class="volume">21</span>:299-<span class="lpage">304</span>. &nbsp;<a href="http://dx.doi.org/10.1093/pubmed/21.3.299">10.1093/pubmed/21.3.299</a>&nbsp;&nbsp;&nbsp;<a href="http://www.ncbi.nlm.nih.gov/pubmed/?term=10528957">pmid:10528957</a></span></div>
               <div id="ref17" class="ref ref17"><span class="label">17</span><span class="mixed-citation web">U.S. National Library of Medicine. RCD (Read codes) – synopsis. 2017. <a href="https://www.nlm.nih.gov/research/umls/sourcereleasedocs/current/RCD/">https://www.nlm.nih.gov/research/umls/sourcereleasedocs/current/RCD/</a>.</span></div>
               <div id="ref18" class="ref ref18"><span class="label">18</span><span class="mixed-citation journal"><span class="person-group author"><span class="name"><span class="surname">Lewis</span><span class="given-names">JD</span></span><span class="name"><span class="surname">Brensinger</span><span class="given-names">C</span></span><span class="name"><span class="surname">Bilker</span><span class="given-names">WB</span></span><span class="name"><span class="surname">Strom</span><span class="given-names">BL</span></span></span>. <span class="ref-article-title">Validity and completeness of the General Practice Research Database for studies of
                        inflammatory bowel disease</span>. <span class="source">Pharmacoepidemiol Drug Saf</span><span class="year">2002</span>;<span class="volume">11</span>:211-<span class="lpage">8</span>. &nbsp;<a href="http://dx.doi.org/10.1002/pds.698">10.1002/pds.698</a>&nbsp;&nbsp;&nbsp;<a href="http://www.ncbi.nlm.nih.gov/pubmed/?term=12051120">pmid:12051120</a></span></div>
               <div id="ref19" class="ref ref19"><span class="label">19</span><span class="mixed-citation journal"><span class="person-group author"><span class="name"><span class="surname">García Rodríguez</span><span class="given-names">LA</span></span><span class="name"><span class="surname">González-Pérez</span><span class="given-names">A</span></span><span class="name"><span class="surname">Johansson</span><span class="given-names">S</span></span><span class="name"><span class="surname">Wallander</span><span class="given-names">MA</span></span></span>. <span class="ref-article-title">Risk factors for inflammatory bowel disease in the general population</span>. <span class="source">Aliment Pharmacol Ther</span><span class="year">2005</span>;<span class="volume">22</span>:309-<span class="lpage">15</span>. &nbsp;<a href="http://dx.doi.org/10.1111/j.1365-2036.2005.02564.x">10.1111/j.1365-2036.2005.02564.x</a>&nbsp;&nbsp;&nbsp;<a href="http://www.ncbi.nlm.nih.gov/pubmed/?term=16097997">pmid:16097997</a></span></div>
               <div id="ref20" class="ref ref20"><span class="label">20</span><span class="mixed-citation journal"><span class="person-group author"><span class="name"><span class="surname">van Staa</span><span class="given-names">TP</span></span><span class="name"><span class="surname">Cooper</span><span class="given-names">C</span></span><span class="name"><span class="surname">Brusse</span><span class="given-names">LS</span></span><span class="name"><span class="surname">Leufkens</span><span class="given-names">H</span></span><span class="name"><span class="surname">Javaid</span><span class="given-names">MK</span></span><span class="name"><span class="surname">Arden</span><span class="given-names">NK</span></span></span>. <span class="ref-article-title">Inflammatory bowel disease and the risk of fracture</span>. <span class="source">Gastroenterology</span><span class="year">2003</span>;<span class="volume">125</span>:1591-<span class="lpage">7</span>. &nbsp;<a href="http://dx.doi.org/10.1053/j.gastro.2003.09.027">10.1053/j.gastro.2003.09.027</a>&nbsp;&nbsp;&nbsp;<a href="http://www.ncbi.nlm.nih.gov/pubmed/?term=14724810">pmid:14724810</a></span></div>
               <div id="ref21" class="ref ref21"><span class="label">21</span><span class="mixed-citation journal"><span class="person-group author"><span class="name"><span class="surname">Louis</span><span class="given-names">E</span></span></span>. <span class="ref-article-title">When it is not inflammatory bowel disease: differential diagnosis</span>. <span class="source">Curr Opin Gastroenterol</span><span class="year">2015</span>;<span class="volume">31</span>:283-<span class="lpage">9</span>. &nbsp;<a href="http://dx.doi.org/10.1097/MOG.0000000000000183">10.1097/MOG.0000000000000183</a>&nbsp;&nbsp;&nbsp;<a href="http://www.ncbi.nlm.nih.gov/pubmed/?term=26039719">pmid:26039719</a></span></div>
               <div id="ref22" class="ref ref22"><span class="label">22</span><span class="mixed-citation journal"><span class="person-group author"><span class="name"><span class="surname">Vavricka</span><span class="given-names">SR</span></span><span class="name"><span class="surname">Spigaglia</span><span class="given-names">SM</span></span><span class="name"><span class="surname">Rogler</span><span class="given-names">G</span></span>&nbsp;et al.&nbsp;<span class="collab">Swiss IBD Cohort Study Group</span></span>. <span class="ref-article-title">Systematic evaluation of risk factors for diagnostic delay in inflammatory bowel disease</span>. <span class="source">Inflamm Bowel Dis</span><span class="year">2012</span>;<span class="volume">18</span>:496-<span class="lpage">505</span>. &nbsp;<a href="http://dx.doi.org/10.1002/ibd.21719">10.1002/ibd.21719</a>&nbsp;&nbsp;&nbsp;<a href="http://www.ncbi.nlm.nih.gov/pubmed/?term=21509908">pmid:21509908</a></span></div>
               <div id="ref23" class="ref ref23"><span class="label">23</span><span class="mixed-citation journal"><span class="person-group author"><span class="name"><span class="surname">Ruigómez</span><span class="given-names">A</span></span><span class="name"><span class="surname">García Rodríguez</span><span class="given-names">LA</span></span><span class="name"><span class="surname">Johansson</span><span class="given-names">S</span></span><span class="name"><span class="surname">Wallander</span><span class="given-names">MA</span></span></span>. <span class="ref-article-title">Is hormone replacement therapy associated with an increased risk of irritable bowel
                        syndrome?</span><span class="source">Maturitas</span><span class="year">2003</span>;<span class="volume">44</span>:133-<span class="lpage">40</span>. &nbsp;<a href="http://dx.doi.org/10.1016/S0378-5122(02)00321-3">10.1016/S0378-5122(02)00321-3</a>&nbsp;&nbsp;&nbsp;<a href="http://www.ncbi.nlm.nih.gov/pubmed/?term=12590009">pmid:12590009</a></span></div>
               <div id="ref24" class="ref ref24"><span class="label">24</span><span class="mixed-citation journal"><span class="person-group author"><span class="name"><span class="surname">Schneeweiss</span><span class="given-names">S</span></span><span class="name"><span class="surname">Seeger</span><span class="given-names">JD</span></span><span class="name"><span class="surname">Maclure</span><span class="given-names">M</span></span><span class="name"><span class="surname">Wang</span><span class="given-names">PS</span></span><span class="name"><span class="surname">Avorn</span><span class="given-names">J</span></span><span class="name"><span class="surname">Glynn</span><span class="given-names">RJ</span></span></span>. <span class="ref-article-title">Performance of comorbidity scores to control for confounding in epidemiologic studies
                        using claims data</span>. <span class="source">Am J Epidemiol</span><span class="year">2001</span>;<span class="volume">154</span>:854-<span class="lpage">64</span>. &nbsp;<a href="http://dx.doi.org/10.1093/aje/154.9.854">10.1093/aje/154.9.854</a>&nbsp;&nbsp;&nbsp;<a href="http://www.ncbi.nlm.nih.gov/pubmed/?term=11682368">pmid:11682368</a></span></div>
               <div id="ref25" class="ref ref25"><span class="label">25</span><span class="mixed-citation journal"><span class="person-group author"><span class="name"><span class="surname">Suissa</span><span class="given-names">D</span></span><span class="name"><span class="surname">Brassard</span><span class="given-names">P</span></span><span class="name"><span class="surname">Smiechowski</span><span class="given-names">B</span></span><span class="name"><span class="surname">Suissa</span><span class="given-names">S</span></span></span>. <span class="ref-article-title">Number needed to treat is incorrect without proper time-related considerations</span>. <span class="source">J Clin Epidemiol</span><span class="year">2012</span>;<span class="volume">65</span>:42-<span class="lpage">6</span>. &nbsp;<a href="http://dx.doi.org/10.1016/j.jclinepi.2011.04.009">10.1016/j.jclinepi.2011.04.009</a>&nbsp;&nbsp;&nbsp;<a href="http://www.ncbi.nlm.nih.gov/pubmed/?term=21816576">pmid:21816576</a></span></div>
               <div id="ref26" class="ref ref26"><span class="label">26</span><span class="mixed-citation journal"><span class="person-group author"><span class="name"><span class="surname">Fine</span><span class="given-names">JP</span></span><span class="name"><span class="surname">Gray</span><span class="given-names">RJ</span></span></span>. <span class="ref-article-title">A proportional hazards model for the subdistribution of a competing risk</span>. <span class="source">J Am Stat Assoc</span><span class="year">1999</span>;<span class="volume">94</span>:496-<span class="lpage">509</span>&nbsp;<a href="http://dx.doi.org/10.1080/01621459.1999.10474144">10.1080/01621459.1999.10474144</a>.</span></div>
               <div id="ref27" class="ref ref27"><span class="label">27</span><span class="mixed-citation web">Public Health England. NHS bowel cancer screening (BCSP) programme. 2017. <a href="https://www.gov.uk/topic/population-screening-programmes/bowel">https://www.gov.uk/topic/population-screening-programmes/bowel</a>.</span></div>
               <div id="ref28" class="ref ref28"><span class="label">28</span><span class="mixed-citation journal"><span class="person-group author"><span class="name"><span class="surname">Kim</span><span class="given-names">SC</span></span><span class="name"><span class="surname">Schneeweiss</span><span class="given-names">S</span></span><span class="name"><span class="surname">Glynn</span><span class="given-names">RJ</span></span><span class="name"><span class="surname">Doherty</span><span class="given-names">M</span></span><span class="name"><span class="surname">Goldfine</span><span class="given-names">AB</span></span><span class="name"><span class="surname">Solomon</span><span class="given-names">DH</span></span></span>. <span class="ref-article-title">Dipeptidyl peptidase-4 inhibitors in type 2 diabetes may reduce the risk of autoimmune
                        diseases: a population-based cohort study</span>. <span class="source">Ann Rheum Dis</span><span class="year">2015</span>;<span class="volume">74</span>:1968-<span class="lpage">75</span>. &nbsp;<a href="http://dx.doi.org/10.1136/annrheumdis-2014-205216">10.1136/annrheumdis-2014-205216</a>&nbsp;&nbsp;&nbsp;<a href="http://www.ncbi.nlm.nih.gov/pubmed/?term=24919467">pmid:24919467</a></span></div>
               <div id="ref29" class="ref ref29"><span class="label">29</span><span class="mixed-citation journal"><span class="person-group author"><span class="name"><span class="surname">Schneeweiss</span><span class="given-names">S</span></span></span>. <span class="ref-article-title">Sensitivity analysis and external adjustment for unmeasured confounders in epidemiologic
                        database studies of therapeutics</span>. <span class="source">Pharmacoepidemiol Drug Saf</span><span class="year">2006</span>;<span class="volume">15</span>:291-<span class="lpage">303</span>. &nbsp;<a href="http://dx.doi.org/10.1002/pds.1200">10.1002/pds.1200</a>&nbsp;&nbsp;&nbsp;<a href="http://www.ncbi.nlm.nih.gov/pubmed/?term=16447304">pmid:16447304</a></span></div>
               <div id="ref30" class="ref ref30"><span class="label">30</span><span class="mixed-citation journal"><span class="person-group author"><span class="name"><span class="surname">Lipsitch</span><span class="given-names">M</span></span><span class="name"><span class="surname">Tchetgen Tchetgen</span><span class="given-names">E</span></span><span class="name"><span class="surname">Cohen</span><span class="given-names">T</span></span></span>. <span class="ref-article-title">Negative controls: a tool for detecting confounding and bias in observational studies</span>. <span class="source">Epidemiology</span><span class="year">2010</span>;<span class="volume">21</span>:383-<span class="lpage">8</span>. &nbsp;<a href="http://dx.doi.org/10.1097/EDE.0b013e3181d61eeb">10.1097/EDE.0b013e3181d61eeb</a>&nbsp;&nbsp;&nbsp;<a href="http://www.ncbi.nlm.nih.gov/pubmed/?term=20335814">pmid:20335814</a></span></div>
               <div id="ref31" class="ref ref31"><span class="label">31</span><span class="mixed-citation journal"><span class="person-group author"><span class="name"><span class="surname">Zietek</span><span class="given-names">T</span></span><span class="name"><span class="surname">Rath</span><span class="given-names">E</span></span></span>. <span class="ref-article-title">Inflammation Meets Metabolic Disease: Gut Feeling Mediated by GLP-1</span>. <span class="source">Front Immunol</span><span class="year">2016</span>;<span class="volume">7</span>:154. &nbsp;<a href="http://dx.doi.org/10.3389/fimmu.2016.00154">10.3389/fimmu.2016.00154</a>&nbsp;&nbsp;&nbsp;<a href="http://www.ncbi.nlm.nih.gov/pubmed/?term=27148273">pmid:27148273</a></span></div>
               <div id="ref32" class="ref ref32"><span class="label">32</span><span class="mixed-citation journal"><span class="person-group author"><span class="name"><span class="surname">Ray</span><span class="given-names">WA</span></span></span>. <span class="ref-article-title">Evaluating medication effects outside of clinical trials: new-user designs</span>. <span class="source">Am J Epidemiol</span><span class="year">2003</span>;<span class="volume">158</span>:915-<span class="lpage">20</span>. &nbsp;<a href="http://dx.doi.org/10.1093/aje/kwg231">10.1093/aje/kwg231</a>&nbsp;&nbsp;&nbsp;<a href="http://www.ncbi.nlm.nih.gov/pubmed/?term=14585769">pmid:14585769</a></span></div>
               <div id="ref33" class="ref ref33"><span class="label">33</span><span class="mixed-citation journal"><span class="person-group author"><span class="name"><span class="surname">Suissa</span><span class="given-names">S</span></span></span>. <span class="ref-article-title">Immortal time bias in pharmaco-epidemiology</span>. <span class="source">Am J Epidemiol</span><span class="year">2008</span>;<span class="volume">167</span>:492-<span class="lpage">9</span>. &nbsp;<a href="http://dx.doi.org/10.1093/aje/kwm324">10.1093/aje/kwm324</a>&nbsp;&nbsp;&nbsp;<a href="http://www.ncbi.nlm.nih.gov/pubmed/?term=18056625">pmid:18056625</a></span></div>
               <div id="ref34" class="ref ref34"><span class="label">34</span><span class="mixed-citation journal"><span class="person-group author"><span class="name"><span class="surname">Jurjus</span><span class="given-names">A</span></span><span class="name"><span class="surname">Eid</span><span class="given-names">A</span></span><span class="name"><span class="surname">Al Kattar</span><span class="given-names">S</span></span>&nbsp;et al</span>. <span class="ref-article-title">Inflammatory bowel disease, colorectal cancer and type 2 diabetes mellitus: The links</span>. <span class="source">BBA Clin</span><span class="year">2015</span>;<span class="volume">5</span>(<span class="supplement">Supplement C</span>):16-<span class="lpage">24</span>. &nbsp;<a href="http://dx.doi.org/10.1016/j.bbacli.2015.11.002">10.1016/j.bbacli.2015.11.002</a>&nbsp;&nbsp;&nbsp;<a href="http://www.ncbi.nlm.nih.gov/pubmed/?term=27051585">pmid:27051585</a></span></div>
               <div id="ref35" class="ref ref35"><span class="label">35</span><span class="mixed-citation journal"><span class="person-group author"><span class="name"><span class="surname">Bähler</span><span class="given-names">C</span></span><span class="name"><span class="surname">Schoepfer</span><span class="given-names">AM</span></span><span class="name"><span class="surname">Vavricka</span><span class="given-names">SR</span></span><span class="name"><span class="surname">Brüngger</span><span class="given-names">B</span></span><span class="name"><span class="surname">Reich</span><span class="given-names">O</span></span></span>. <span class="ref-article-title">Chronic comorbidities associated with inflammatory bowel disease: prevalence and impact
                        on healthcare costs in Switzerland</span>. <span class="source">Eur J Gastroenterol Hepatol</span><span class="year">2017</span>;<span class="volume">29</span>:916-<span class="lpage">25</span>. &nbsp;<a href="http://dx.doi.org/10.1097/MEG.0000000000000891">10.1097/MEG.0000000000000891</a>&nbsp;&nbsp;&nbsp;<a href="http://www.ncbi.nlm.nih.gov/pubmed/?term=28471826">pmid:28471826</a></span></div>
               <div id="ref36" class="ref ref36"><span class="label">36</span><span class="mixed-citation journal"><span class="person-group author"><span class="name"><span class="surname">Sharma</span><span class="given-names">M</span></span><span class="name"><span class="surname">Nazareth</span><span class="given-names">I</span></span><span class="name"><span class="surname">Petersen</span><span class="given-names">I</span></span></span>. <span class="ref-article-title">Trends in incidence, prevalence and prescribing in type 2 diabetes mellitus between
                        2000 and 2013 in primary care: a retrospective cohort study</span>. <span class="source">BMJ Open</span><span class="year">2016</span>;<span class="volume">6</span>:e010210. &nbsp;<a href="http://dx.doi.org/10.1136/bmjopen-2015-010210">10.1136/bmjopen-2015-010210</a>&nbsp;&nbsp;&nbsp;<a href="http://www.ncbi.nlm.nih.gov/pubmed/?term=26769791">pmid:26769791</a></span></div>
            </div>
         </div>
      </div>
   </body>
</html>